Official Protocol Title:
NCT number:
Document Date:
[STUDY_ID_REMOVED]
A Multi-Center, Open Label, Extension Study Evaluating 
the Safety and Efficacy of Bomedemstat for the 
Treatment of Patients with Myeloproliferative Neoplasms 
(MPNs) Enrolled in a Prior Bomedemstat Clinical Study
 13-December-2023
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	1Protocol	Title: A	Multi-Center,	 Open	 Label,	Extension	 Study	 Evaluating	 the	
Safety	 and	Efficacy	 of	Bomedemstat	 forthe	Treatment	 of	
Patients	 with	Myeloproliferative Neoplasms	 (MPNs)	Enrolled
in	a	Prior	 Bomedemstat Clinical	Study
Protocol	No.: IMG-7289-CTP-202/	MK-3543-005
Investigational	Product: Bomedemstat (IMG-7289	/	 MK-3543)
Indication: Myeloproliferative	Neoplasms
Study	Phase: Phase	2
EudraCT	Number: 2021-002452-37
IND	Number: 130,789
Sponsor: Imago	 BioSciences,	 Inc.,	a	subsidiary	 of	Merck	 &	Co.,	Inc.	126	East	
Lincoln	Avenue,	Rahway,	NJ	07065,	USA
Version	and	Date:
Amendment	0 2 13	December	2023
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	2Sponsor	Signatory
Typed	Name:
Title:Date
Protocol -specific	Sponsor	contact	information	can	be	found	in	the	 Investigator	Study	File	
Binder	(or	equivalent).
Investigator	Signatory
I	agree	 to	conduct	 this	clinical	 study	 in	accordance	 with	the	design	 outlined	 in	this	
protocol	and	to	abide	by	all	provisions	of	this	protocol.
Typed	Name:
Title:Date
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	3DOCUMENT HISTORY
Document Date	of	Issue Overall	Rationale
Amendment	 2 13-DEC-2023 This	change	 was	made	 to	address	 study	extension.	
Participants	 from	this	study	 will	be	eligible	 to	enroll	 in	
another	 bomedemstat	 extension	 study	 at	any	point	
before	this	 study	ends.
Amendment	1 14-JUN-2023 This	change	 was	made	 to	address	 Non-Merck	 protocol	
template .	The	rationale	 is	further	 supported	 by	
acquisition	 of	Imago BioSciences ,	Inc.by	Merck	 &	Co.,	
Inc.	This	conversion	 resulted	 only	in	an	entity	 name	
change	and	u pdate	to	the	address.
Original	Protocol 11-JUL-2021 Not	applicable
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	4PROTOCOL AMENDMENT SUMMARY OF CHANGES
Amendment: 02
Overall Rationale for the Amendment:
This change was made to address study extension. Participants from this study will be eligible 
to enroll in another bomedemstat extension study at any point before this study ends.
Summary of Changes Table
Section Number 
and Name Description of Change Brief Rationale
Primary Reason for Amendment
Section 9.4.1, End 
of Treatment 
(EoT)Language added to allow eligible participants 
from this extension study to enroll in another 
extension study using bomedemstat This change was made to address study 
extension. Participants from this study will be 
eligible to enroll in another bomedemstat 
extension study at any point before this study 
ends.
Section Number 
and Name Description of Change Brief Rationale
Additional Changes
Title Page Added complete address for Sponsor To provide complete address for Sponsor
Section 2 ,
Protocol SynopsisLanguage added to allow eligible participants 
from this extension study to enroll in another 
extension study using bomedemstatRefer to the rationale for Section 9.4.1
Section 5. 1,
OverviewLanguage added to allow eligible participants 
from this extension study to enroll in another 
extension study using bomedemstatRefer to the rationale for Section 9.4.1
Section 9.4.2, 
End of 
Study/Early 
Termination VisitLanguage added to allow eligible participants 
from this extension study to enroll in another 
extension study using bomedemstatRefer to the rationale for Section 9.4.1
Section 11.2.5 , 
For Participant s
Who Consent To 
Another 
Bomedemstat 
Extension StudyAdded section To provide guidance for investigator for 
reporting a ll AEs, SAEs, and other reportable 
safety events
Throughout Minor administrative, formatting, grammatical, 
and/or typographical changes w ere made 
throughout the document.To ensure clarity and accurate interpretation of 
the intent of the protocol
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	5Table	of	Contents
DOCUMENT HISTORY ................................ ................................ ................................ ................................ ................. 3
PROTOCOL AMENDMENT SUMMARY OF CHANGES ................................ ................................ ............... 4
1 LIST OF ABBREVIATIONS AND DEFINITION OF TERMS ................................ .............................. 9
2 PROTOCOL SYNOPSIS ................................ ................................ ................................ ................................ ....13
3 INTRODUCTION ................................ ................................ ................................ ................................ ................. 21
3.1 Backgro und on the Disease to be Treated ................................ ................................ ............................ 21
3.2 Background on the Drug Target ................................ ................................ ................................ .............. 21
3.3 Background on LSD1 in Myeloid Neoplasia Pre -Clinical Studies ................................ .............. 23
3.4 Background on Bomedemstat (IMG -7289/MK -3543) ................................ ................................ .....24
3.5 Potential Clinical Risks and Benefits when Dosing an LSD1 Inhibitor ................................ .....24
3.6 Bomedemstat Dose Justification ................................ ................................ ................................ ............. 25
3.6.1 Rationale for and Safety of the Proposed Bomedemstat Dose ................................ ............. 25
3.6.2 Rationale for the Bomedemstat Dosing Schedule ................................ ................................ ....26
4 HYPOTHESIS AND OBJECTIVES ................................ ................................ ................................ ............... 27
4.1 Objectives ................................ ................................ ................................ ................................ ....................... 27
5 INVESTIGATIONAL PLAN ................................ ................................ ................................ ............................ 27
5.1 Overview ................................ ................................ ................................ ................................ ......................... 27
6 STUDY POPULATION ................................ ................................ ................................ ................................ ......29
6.1 Study Entry Criteria ................................ ................................ ................................ ................................ .....29
6.1.1 Inclusion Criteria ................................ ................................ ................................ ................................ 29
6.1.2 Exclusion Criteria ................................ ................................ ................................ ............................... 29
6.2 Patient Enrollment ................................ ................................ ................................ ................................ .......30
6.3 Patient Withdrawal ................................ ................................ ................................ ................................ ......30
6.4 Patie nt Care Guidelines ................................ ................................ ................................ .............................. 30
6.5 Prohibited Medications ................................ ................................ ................................ ............................... 31
7 STUDY PRODUCT ................................ ................................ ................................ ................................ .............. 32
7.1 Formulation, Labeling, Packaging and Storage ................................ ................................ .................. 32
7.1.1 Formulation ................................ ................................ ................................ ................................ ..........32
7.1.2 Packaging and Labeling ................................ ................................ ................................ ................... 32
7.1.3 Storage ................................ ................................ ................................ ................................ ................... 32
7.2 Dispensin g, Administration, Dosage and Missed Doses ................................ ................................ .32
7.2.1 Dispensing ................................ ................................ ................................ ................................ ............ 32
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	67.2.2 Administration ..................................................................................................................................... 33
7.2.3 Dosage .................................................................................................................................................... 33
7.2.4 Missed Doses ....................................................................................................................................... 34
7.2.5 Interruption of Dosing ....................................................................................................................... 34
8 SAFETY A DVISORY BOARD (SAB) REVIEWS AND MANAGEMENT OF STUDY 
TOXICITIES, INCLUDING STOPPING RULES ............................................................................................... 34
8.1 Safety Advisory Board (SAB) Reviews ................................................................................................ 34
8.2 Management of Study Toxicities ............................................................................................................ 35
8.2.1 Hematologic Toxicity ........................................................................................................................ 35
8.2.2 Stopping Rules .................................................................................................................................... 35
9 STUDY ASSESSMENTS ................................................................................................................................... 35
9.1 Enrollment Period ........................................................................................................................................ 37
9.1.1 Informed Consent Visit ..................................................................................................................... 37
9.1.2 Eligibility Assessment ....................................................................................................................... 38
.38
.38
.39
.40
.41
.41
.41
.42
.43
.43
.43
.44
.44
.44
.45
10 LABORATORY SAMPLING FOR SAFETY AND PD ANALYSIS ................................................ 46
10.1 Laboratory Measures ................................................................................................................................... 46
10.1.1 Local Laboratory Measures ............................................................................................................. 47
10.1.2 Central Laboratory Measures .......................................................................................................... 47
11 SAFETY ................................................................................................................................................................... 48
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	711.1 Pregnancy ................................ ................................ ................................ ................................ ....................... 48
11.2 Adverse Events ................................ ................................ ................................ ................................ ............. 49
11.2.1 Adverse Event Intensity ................................ ................................ ................................ ................... 50
11.2.2 Adverse Event Relatedness ................................ ................................ ................................ ............. 51
11.2.3 Serious Adverse Events ................................ ................................ ................................ .................... 51
11.2.4 Reporting Serious Adverse Events ................................ ................................ ............................... 52
11.2.5 For Participants Who Consent To Another Bomedemstat Extension Study ................... 53
12 ANALYSIS AND STATISTICAL CONSIDERATIONS ................................ ................................ .......53
12.1 General Considerations ................................ ................................ ................................ .............................. 53
12.2 Power ................................ ................................ ................................ ................................ ............................... 53
12.3 Treatment Assignment and Blinding ................................ ................................ ................................ .....53
12.4 Study Endpoints ................................ ................................ ................................ ................................ ............ 53
12.4.1 Primary Endpoints ................................ ................................ ................................ .............................. 53
12.4.2 Exploratory Endpoints ................................ ................................ ................................ ...................... 54
12.5 Data Analysis ................................ ................................ ................................ ................................ ................. 55
12.5.1 Safety and Tolerability Data Analysis ................................ ................................ ......................... 55
12.5.2 Efficacy Data Analysis ................................ ................................ ................................ ..................... 56
13 STUDY ADMINISTRATION ................................ ................................ ................................ .......................... 57
13.1 Ethical Considerations ................................ ................................ ................................ ................................ 57
13.2 Participation Information Sheet/Consent Form (PISCF) ................................ ................................ .57
13.3 Institutional Review Board (IRB), Independent Ethi cs Committee (IEC) and Human 
Research Ethics Committee (HREC) ................................ ................................ ................................ ................... 57
13.4 Study or Site Termination ................................ ................................ ................................ ......................... 58
13.5 Study Monitoring Requirements ................................ ................................ ................................ ............. 58
13.6 Quality Assurance ................................ ................................ ................................ ................................ ........59
13.7 Confidentiality ................................ ................................ ................................ ................................ ............... 59
14 INVESTIG ATOR REQUIREMENTS ................................ ................................ ................................ ............ 60
14.1 Protocol Adherence ................................ ................................ ................................ ................................ .....60
14.2 Source Documentation ................................ ................................ ................................ ............................... 61
14.3 Direct Access to Source Documentation ................................ ................................ .............................. 61
14.4 Case Report Forms ................................ ................................ ................................ ................................ ......61
14.5 Study Drug Accountability ................................ ................................ ................................ ....................... 61
14.6 Disposal of Study Drug ................................ ................................ ................................ .............................. 62
14.7 Training of Staff ................................ ................................ ................................ ................................ ...........62
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	814.8 Clinical Study Report .................................................................................................................................. 62
14.9 Retention of Records ................................................................................................................................... 62
15 REFERENCES ....................................................................................................................................................... 63
16 APPENDICES ........................................................................................................................................................ 66
..66
..66
..68
..71
..72
16.2 Criteria for Grading Myelofibrosis (Arber et al. , 2016)* ................................................................ 73
16.3 Eastern Cooperative Group Perfor mance Status ................................................................................ 73
16.4 Revised IWG -MRT and ELN Response Criteria for MF ................................................................ 74
16.5 Revised Response Criteria for ET:  IWG -MRT and ELN Consensus 2013 (Barosi et al., 
2013) ............................................................................................................................................................................ 76
16.6 Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score  (MPN -
SAF TSS) – 7-Day Recall ....................................................................................................................................... 77
16.7 Myeloproliferative Neoplasm Symptom Assessment Form (MPN -SAF).................................. 78
16.8 Patient Global Impression of Change .................................................................................................... 80
16.9 Remote Data Review .................................................................................................................................. 81
16.9.1 Risk Assessment ................................................................................................................................ .81
16.9.2 Security Measures .............................................................................................................................. 81
16.9.3 Processes ............................................................................................................................................... 81
16.9.3.1 Direct, Controlled Remote Access totheSystems Used bytheTrial Siteto
Manage theSource Documents/Source Data.......................................................................................... 82
16.9.3.2 ForPassive Access toOriginal Documents/Original Data via Live Image
Transmission ..................................................................................................................................................... 82
16.9.3.3 Passing on Redacted Copies of Original Documents and Documents with Original 
Data ........................................................................................................................................................ 82
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	91LIST OF ABBREVIATIONS AND DEFINITION OF TERMS
Abbreviation Definition
<,	≤,	>,	≥ less	than,	less	than	or	equal	 to,	greater	than,	greater	than	or	equal	to
± plus	or	minus
Ac acetylation
ADL activities	of	daily	living
AE adverse	event
ALP alkaline	phosphatase
ALT alanine	aminotransferase
AML acute	myeloid	 leukem ia
ANC absolute	neutrophil	count
aPTT activated	partial	thromboplastin	time
AST aspartate	transaminase
ATP Additional	Treatment	Period
BCR-ABL breakpoint	cluster	region -Abelson
BM bone	marrow
Bomedemstat	
(IMG-7289	/	MK -
3543)N-[(2S)-5-{[(1R,2S) -2-(4-fluorophenyl)cyclopropyl]amino} -1-(4-
methylpiperazin -1-yl)-1-oxopentan -2-yl]-4-(1H-1,2,3-triazol -1-
yl)benzamide,	bis -tosylate	salt
BMMC bone	marrow	mononuclear	cell
BUN blood	urea	nitrogen
°C degrees	Centigrade
CALR calreticulin	
CBC complete	blood	count
CD cluster	of	differentiation
CFR Code	of	Federal	Regulations
cGMP current	Good	Manufacturing	Practices
CI confidence	interval
CIOMS Council	for	International	Organizations	of	Medical	Sciences
Clinical	 Benefit not	meeting	 “progressive	disease ”criteria	as	per	 Section	 16.4(for	MF	
patients)	and	 Section	 16.5	(for	ET	patients)	 and	safely	tolerating	IMG -
7289,	as	determined	by the	Principal	Investigator
CMH Cochran -Mantel -Haenszel
CoREST Co-repressor	for	RE1 -silencing	transcription	factor
COVID -19 Coronavirus	disease -2019
CR complete	remission	or	response
CRO contract	research	 organization
CRP c-reactive	protein
CT computerized	tomography
CTCAE Common	Terminology	Criteria	for	Adverse	Events
CV co-efficient	of	variation
Cxcl chemokine	(C -X-C	Motif)	ligand
CXCR4 chemokine	(C -X-C	motif)	receptor	4
CYP cytochrome	P450
D,	d day
DILI Drug-induced	liver	injury
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	10Abbreviation Definition
DNA deoxyribonucleic	acid
DNMT DNA-methyltransferase
Dpi pharmacodynamic	dose;	the	estimated	dose	of	IMG -7289	needed	in	
humans	that	provides	sufficient	exposure	to	inhibit	normal	
hematopoiesis	safely	during	a	 fraction of	the	24 -hour	dosing	cycle
EC Ethics	Committee	
ECOG Eastern	Cooperative	Oncology	Group
eCRF electronic	case	report	form
EDC electronic	data	capture
EFS event	free	survival
ELN European	 Leukem ia	Network
EMH extramedullary	 hematopoiesis
EMR electronic	medical	record
EoS End	of	Study
EoT End	of	Treatment
EPO erythropoietin
ESC embryonic	stem	cell
ET essential	thrombo cythemia;	Early	Termination
FAD flavin	adenine	dinucleotide
Free	base	of	IMG -
7289N-[(2S)-5-{[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino} -1-(4-
methylpiperazin -1-yl)-1-oxopentan -2-yl]-4-(1H-1,2,3-triazol -1-
yl)benzamide,	 free	base
FSH follicle	stimulating	hormone
g	or	gm gram
g/dL gram	per	deciliter
GCP Good	Clinical	 Practice
G-CSF gram	colony	 stimulating	factor
GFI1 growth	factor	independent	1	transcription	factor
GFP green	fluorescent	protein
GGT gamma	glutamyltransferase
GM-CSF granulocyte -macrophage	colony	stimulating	factor
GMP Good	Manufacturing	Practices
H histone
HAV hepatitis	A	virus
Hb hemoglobin
HBcAb hepatitis	B	core	antibody
HBsAb hepatitis	B	surface	antibody
HBsAg hepatitis	B	surface	antigen
HCV hepatitis	C	virus
HDAC histone	deacetylase
HIPAA Health	Insurance	Portability	and	Accountability	Act
HIV human	immunodeficiency	virus
HREC Human	Research	Ethics	Committee
HSC hematopoietic	stem	cell
ICF informed	 consent	 form
ICH International	 Council	 for	Harmonisation
IEC Independent	Ethics	Committee
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	11Abbreviation Definition
IL interleukin
IMG-7289 bomedemstat,	 N-[(2S)-5-{[(1R,2S)-2-(4-
fluorophenyl)cyclopropyl]amino} -1-(4-methylpiperazin -1-yl)-1-
oxopentan -2-yl]-4-(1H-1,2,3-triazol -1-yl)benzamide,	 bis-tosylate	salt
INR international	normalized	ratio
IRB Institutional	Review	Board
ITT Intent	to	Treat
IUD intrauterine	device
IWG-MRT International	Working	Group	for	 Myelofibrosis	Research	and	
Treatment
JAK Janus	Kinases
K lysine
KD knockdown	
KDM1A lysine -specific	demethylase	1
Kg kilogram
L litre
LDH lactate	dehydrogenase
LIC leukem ia	initiating	cell
LPE Limited	Physical	Exam
LSD1 lysine -specific	demethylase	1
LSDi LSD1	inhibition	or	inhibitors
MAO;	MAOI monoamine	oxidase(s);	monoamine	oxidase	inhibitor(s)
MDS myelodysplastic	syndrome
me;	Me methyl;	methylation
MedDRA Medical	Dictionary	for	Regulatory	Activities
MF myelofibrosis
mg milligram
mg/kg milligram	per	kilogram
mg/kg/d milligram	per	kilogram	per	day
mL milliliter
MPL myeloproliferative	 leukem ia	virus	oncogene,	thrombopoietin	receptor
MPN myeloproliferative	neoplasias	or	neoplasms ,	myeloproliferative	
diseases
MPN10 The	equivalent	of	the	MPN -SAF	TSS
MPN-SAF;	
MPN-SAF	TSSMyeloproliferative	Neoplasm	Symptom	Assessment	Form ;	
Myeloproliferative	Neoplasm	Symptom	Assessment	Form	Total	
Symptom	S core
MPP multipotent	progenitor
MRI magnetic	resonance	imaging
mRNA messenger	RNA
MYB V-Myb	Avian	Myeloblastosis	Viral	Oncogene	Homolog
NCICTCAE National	Cancer	Institute Common	Terminology	Criteria	for	Adverse	
Events
nM nanomolar
NSAID nonsteroidal	anti -inflammatory	drug
NuRD nuclear	remodeling	and	histone	deacetylase
OCT4 octamer -binding	transcription	factor	4
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	12Abbreviation Definition
ONC Office oftheNational Coordinator forHealth Information Technology
OS overall	survival
PBMC peripheral	blood	mononuclear	cell
PD pharmacodynamics
PE physical	examination
PET-MF post-essential	thrombo cythemia	myelofibrosis
PFS progression	free	survival
PGIC Patient	Global	Impression	of	 Change
Ph phosphorylation	
PI Principal	Investigator	(at	each	site	responsible	for	patient	care)
PISCF Participant	Information	Sheet/Consent	Form
PMF primary	myelofibrosis
PR partial	remission	or	response
PT prothrombin	time
PV polycythemia	vera
QD once	daily
RBC red	blood	cell
REST RE-1	silencing	transcription	factor
RNA ribonucleic	acid
SAB Safety	Advisory	Board
SABP Safety	Advisory	Board	Plan
SAE serious	adverse	event
SAP Statistical	Analysis	Plan
SD standard	deviation
sh short	hairpin
SOX2 sex	determining	region	Y -box	2
SRM Study	Reference	Manual
SRY sex	determining	region	Y
STAT signal	transducer	 and	activator	 of	transcription
TCP tranylcypromine
TF transcription	factor
TP Treatment	Period
µL microliter
µM micromolar
Ub ubiquitination	
VPN virtual	private	network
WBC white	blood	cell
WHO World	Health	Organization
WOCBP women	of	child -bearing	potential
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	132PROTOCOL SYNOPSIS
Protocol	 Title:	 	A	Multi-Center,	 Open	 Label,	 Extension	 Study	 Evaluating	 the	Safety	 and	
Efficacy	 of	Bomedemstat for	the	Treatment	 of	Patients	 with	Myeloproliferative	 Neoplasms	
(MPN)	 Enrolled	in a	Prior	 Bomedemstat Clinical	Study
Protocol	No:		 IMG-7289-CTP-202/	MK-3543-005
Amendment	No: 01	
Sites:	 	Up	to	25	sites	in	Australia,	 New	Zealand,	 Italy,	Germany,	 Hong	 Kong,	 UK	and	US.		All	
sites	will	have	previously	participated	in	a	bomedemstat	study.
Study	Objectives:		 The	objectives	of	this	extension	study	are	to :		
Continue	 to	assess	 the	safety,	 tolerability	 and	efficacy	 ofbomedemstat	 in	patients	 who	
received	bomedemstat	in	a	prior	study
Measure	 the	extent	 and	durability	 of	bomedemstat	 treatment	 effects on	exploratory	
endpoints	including	any	impact	of	bomedemst at	on	the	natural	history	of	MF	and	ET
Investigational	 Drug:	 The	active	 drug	substance	 is	identified	 as	bomedemstat	 (also	known	
as	IMG-7289 /	MK-3543).	Bomedemstat	 is	an	irreversible	 inhibitor	 of	LSD1.	 The	chemical	
name	 is:	
N-[(2S)-5-{[(1R,	2S)-2-(4-fluorophenyl)	 cyclopropyl]amino} -1-(4-methylpiperazin -1-yl)-1-
oxopentan -2-yl]-4-(1H-1,2,3-triazol -1-yl)benzamide,	 bis-tosylate	 salt.		Bomedemstat	 will	be
supplied	as	capsules	in	multiple	strengths.	Reference	the	Pharmacy	Manual	for	details.
Study	Population:	 Thisstudy	will	enroll	approximately	80	patients	with	an	MPN	that	meet	
the	eligibility	criteria.			
Methodology:	 	This	is	a	multi-center,	 open-label	extension	 study	 to	assess	 the	long-term	
safety	 and	efficacy	 of	bomedemstat	 administered	 orally	 once	daily	in	patients	 with	an	MPN	
who	participated	 in	a	prior	bomedemstat	 study	 such	as,	but	not	limited	 to,	IMG-7289-CTP-
102and	IMG-7289-CTP-201	(referred	 to	hereafter	 as	‘feeder	 studies’).	 	Details	 of	the	
extension	 study	 and	a	copy	of	the	informed	 consent	 form	(ICF)	 should	 be	provided	 to	the	
patient	 prior	to	their	anticipated	 final	visit	in	the	feeder	 study.	Informed	 consent should	 be	
obtained	 at,	or	before,	 the	feeder	 study’s	 finalvisit.		It	is	intended	 that	patients	 transition	
directly	into	this	extension	study	with	no	interruption	of	dosing .		
Under	 the	following	 circumstances,	 provided	 the	Principal	 Investigator	 (PI)	deemsit	safe	and	
clinically	 appropriate,	 patients	 may	remain	 off	bomedemstat	 for	up	to	2	weeks	 prior	 to	
entering	the	extension	study:			
Patient	 does	not	provide	 consent	 bytheirfinalfeeder	 study	 visit.		Such	patients	 will	
have	an	allowance	of	14	days	to	c onsent	to	 andinitiate	dosing	in	the	extension	study.
Patient	requires	a	dose	hold	per	Titration	Assessment
There	 is	an	administrative	 need	to	interrupt	 bomedemstat	 dosing	 (i.e.,	pending	 any	
necessary	health	authority	or	local/ site	approval s).
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	14Note:	 	Fourteen	(14)days	without	 bomedemstat	 dosing	 priorto	first	dose	in	the	extension	
study	 may	not	be	exceeded	without	 written	 Sponsor	Medical	Monitor	approval.
A	Safety	Advisory	Board	(SAB)	will	perform	reviews	of	safety	parameters in	accordance	with	
a	Safety	Advisory	Board	Plan	 to	assess	the	continued	use	of	bomedemstat	 per	protocol.
Study	Conduct:		
Eligibility	criteria	will	be	assessed	based	on	the	patient’s	 finalvisit	in	their	feeder	study. 		The	
first	visit	in	the	extension	 study	 is	the	‘Transition	 Visit’.		Ideally,	 patients	 will	commence	
treatment	 upon	completion	 of	a	Treatment	 Period (TP)in	the	feeder	 study;	 however,	 some	
patients	will	need	to	transition	to	this	extension	study	at	differing timepoints	and	so	 the	final	
feeder	 study	visit	and	the	Transition Visit	will	need	to	be	linked	 (i.e.,	patients	 completing	 their	
feeder	 study	 at	the	end	of	a	TP	will	enter	the	extension	 study	 at	TP1	Day	1;	patients	 completing	
their	feeder	 study	at	a	‘Day	85’	visit	will	enter	the	extension study at	TP1Day	85)to	maintain	
the	correct	 visit	schedule .		Patients	 will	be	dosed	 in	TPs,	with	each	TP	comprised	 of	daily	
treatment	 with	bomedemstat	 for	169	days.	 	Qualifying	 patients	 may	continue	 to	receiv e	
bomedemstat	for	multiple	TPs,	each	comprising	an	ad ditional	169	days	of	treatment.
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	15days)	post	last	 procedure datein	the	feeder	study .				
At	each	Day	169	visit,a	Qualification	 Assessment	 will	be	made	 to	determine	 whether	 the	
patient	 is	continuing	 to	derive	 clinical	 benefit	 (defined	 as	not	meeting	 “progressive	 disease”	
criteria ,as	per	Appendices	 16.4and	16.5for	MF	and	ETpatients ,respectively ,	and	safely	
tolerating	 bomedemstat ),	thereby	 determining	 patient	 qualification	 for	continued	
bomedemstat	use	 viaentry	 into	another	 TP.		Patients	 who	qualify	for	another	 TPshould
transition	 without	 interruption	 in	dosing. 		Patients	 who	do	not	qualify	 will	discontinue	
bomedemstat ,immediately	undergo	an End	of	Treatment	(EoT )visit	and	 have	theFollow- up	
Period	 End	of	Study	 (EoS) visit scheduled. If	available,	 patients	 who	qualify	 for	another	
bomedemstat	 extension	 study	 can	undergo	 an	EoT	visit	 and	transition	 to	the	next	 extension	
study	without	the	need	for	a	Follow	up	Period /EoS	visit.
Bomedemstat	 Dosing:	 	All	patients	 will	be	dosed	 with	bomedemstat	 dailywithdose-titration	
contingent	on	the Titration	A ssessment	performed	at	every	 TP	visit.		 Patients	receiving	their	
first	extension	 study	 dose	with	no	interruption	 in	dosing	 will	have	a	Titration Assessment	
performed	at	 the	Transition	 Visit	to	determin e	if	atitration	 is	needed.	 	Patients	 requir ingan	
interruption	 in	dosing	 will	have	a	Titration	Assessment	 performed	 at	the	Transition	 Visit	to	
determine	 if	theywillcommenc eat	the	same	 daily	dose	of	bomedemstat	 being	 taken	 at	the	
conclusion	 of	their	feeder	 study or	if	a	down- titration	 or	dose	hold	is	needed (up-titrations	
are	not	permitted) .		Titration	 targets	 and	rules,specific	 to	the	underlying	 MPN,aredetailed	
in	the	Study	 Reference	 Manual ,Pharmacy	 Manual ,	and	A ppendix	 16.1.3 and	16.1.4 .		The	upper	
limit	for	titration	is	6	mg/k g/day.	
Study	Duration :		 	
.
Study	 Assessments :		The	key	study	 assessments	 outlined	 below	 are	also	summarized	 in	
Study	Assessments ,Section	9 ,and	in	the	Schedule	of	Assessments ,Section	 16.1.		
*Patients	entering	the	extension	study	at	the	final	visit	of	the	feeder	study	will	undergo	the	asterisked	
procedures	 in	association	 with	the	feeder	 study;	 the	assessments	 should	not	 be	duplicated.	 	Patients	
entering	 the	extension	 study	 that	require	 interruption	 of	dosing	 must	 undergo	 the	asterisked	
procedures.
Limited	 Physical	 Examinations	 (LPE): 	
		LPEs	include	 weight,	
vital	signs,	 a	review	 of	body	 systems	 to	assess	 change	 from	 previous	 LPE	and	spleen	
measurement.		
	
	
	
		
		
	
CCI
CCI
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	16following	 the	last	assessment	 in	the	feeder	 study	 for	as	long	as	the	patient	 continues	 to	qualify	
for	treatment,	 and	at	the	Suspected	 Relapse,	 EoT,EoSand	ETvisits.Bone	marrow	 sampling	
will	not	be	repeated	if performed in	the	prior	5 weeks.
†Aspirate	sa mple	should	be	optimally	obtained	within	the	first	pull.	Do	not	collect	after	a	second	pull	attempt .
Local	L aboratory	 Assessment s:The	following	panels (Section	 10.1.1 details	analytes) will	be	
performed	 as	perbelow,	 and	at	the	Transition	 Visit*,	Suspected Relapse,	 EoT,	EoSand	ET
visits:
Genomic	 and	Correlative	 Research	 Analyses :		The	following	 will	be	collected	 at	the	time-
points	 noted	 below ,and	(unless	 bone	marrow	 was	performed	 in	the	prior	5weeks)	 at	the
Suspected Relapse ,EoT,EoSand	ET	visits .		Genomic	 mutant	 allele	 burden	 will	be	analyzed .
Also,	s ome	or	all	of	each	 sample	may	be	placed	in	long -term	storage	for	potential	correlative
research studies.
Titration	 Assessment :		At	every visitduring	 the	TP,the	local	laboratory	 hematology	 panel will	
be	assessed	 for	potential	 dose	titration in	accordance	 with	the	titration	 rules	detailed	 in	the	
Study	Reference	Manual	and	Pharmacy	manual .	
Qualification	 Assessments :		At	Day	169of	each	TP	completed ,Investigators	 will	assess	
whether	 the	benefit- risk	of	bomedemstat	 favors	 continued	 treatment,	 thereby	 determining	
patient	 qualification	 for	entry	into	another	 TP.		Qualifying	 patients	 may	enter	another	 TP	upon	
completing	 the	Day	169	visit.	 Patients who do	not	qualify will	discontinue	 bomedemstat ,
undergo	an	 EoT	visit and	proceed	with	the	Follow -up	Period EoS	visit .
The	below	assessments	are	required	 ONLY if	required	in	the	feeder	study:
ECOG	 Performance	 Status (Appendix	 16.3):On	Day	169	of	each	TP	completed,	 and	at	the	
Suspected	Relapse,	 EoT,EoSand	ETvisits.	
CCI
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	17Eligibility	Criteria :	
Patients	must	meet	 all	Inclusion	and	 noExclusion	Criteria.	
Inclusion	Criteria:
1.Completed	 at	least	one	Treatment	 Period	 (TP)	in	a	prior	 bomedemstat MPN	protocol	
(such	as,	but	not	limited	to,	IMG- 7289-CTP-102	or	IMG -7289-CTP-201).
2.In	the	estimation	 of	the	Investigator,	 the	risk-benefit favors	 continued	 dosing	 with	
bomedemstat .
Exclusion	Criteria:
1.Ongoing	participation	in	another	investigational	study	(except	observational	studies) .
2.A	history	 of	non-compliance	 in	a	prior	bomedemstat	 study	 (excluding	 dose	suspensions	
that	were	medically	warranted).
3.Current	use	of	a	p rohibited	medication	(e.g.,	romiplostim).
4.Medical,	 psychiatric,	 cognitive,	 or	other	 conditions	 that,	in	the	Investigator’s	 opinion,	
compromise	the	patient’s	 safety,	ability	to	 give	informed	 consent,	 or	comply	with	the	trial	
protocol .
5.Females	 who	are	pregnant	 or	breastfeeding or	plan	to	become	 pregnant	 or	breastfeed	
during	the	study.
6. 	
	
		 	
	
	
		
	
		
Note:		In	the	UK,	male patients with	a	pregnant	partner	must	agree	to	use	a	condom	to	avoid	
exposure	to	the	developing	child.		Note:		In	Germany,	use	of	computerised	tomography	(CT)	is	not	permitted	 for	patients	unable	to	
undergo	magnetic	resonance	imaging	(MRI).		Only	MRI	is	permitted	for	study	purposes.
CCI
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	18Patient	Care Guidelines :		
Patient	 care	 guidelines	 are	provided	 for	Investigator	 and	site	staff	consideration	 and	
recognize	 the	standard	 of	care	across	 global	 institutions	 will	vary.		The	following	 are	not	
protocol	requirements.
For	all	patients :
1.In	general,	supportive	care	(transfusions,	administration	of	anti -fungals,	etc.)	should	be	
maintained	 in	accordance	 with	institutional	 policy. 		(Note:	 	Transfusions	 must	 be	
adequately	 recorded	 in	the	source	 documents	 to	facilitate	 data	entry	 of	the	study	
required	parameters	 [i.e.,	type	of	blood	product	transfused,	units,	total	volume ]).
2.Patients	 taking	 medications	 with	the	potential	 to	induce	 or	inhibit	 CYP3A4	 or	CYP2D6	
should	 be	monitored	 closely	 for	potential	 effects	 of	co-administration;	 partic ular	
attention	should	be	given	to	anti -infectives	in	the	azole class.
3.There	 are	no	restrictions	 to,	or	recommendations	 on	the	timing	 of,	administration	 of	
vaccines	(i.e.,	 coronavirus	disease	2019	 [COVID -19]vaccination) .
4.Cessation	 of	bomedemstat	 is	associated	 with	a	 rebound	 in	thrombopoiesis ,and	platelet	
counts may	exceed	 baseline	 in	thepatient.	 When	 bomedemstat	 is	discontinued,	
platelet	 countsmust	 be	monitored	 closely	 and	the	timing	 of	the	start	 of	an	
alternative	 therapy	 should	 take	 the	expected	 rebound	 ofplatelets	 into	
consideration .		
 	
	
5. 	
	
	
	
Prohibited	 Medications/Treatments:		
Please	consult	the	Medical	Monitor	with	any	questions	pertaining	to	prohibited	medications.
1.All	cytotoxic agents ,with	noted	 exception	 of	hydroxyurea	 for	MF	patients	 as	per	
Guidelines
2.All	hematopoietic	 growth	 factors:	 romiplostim, eltrombopag,	 granulocyte	 and	
granulocyte -macrophage	 colony	 stimulating	 factor	 (G-CSF	 and	 GM-CSF)	 and	
erythropoietin	(EPO)
3.Monoamine	oxidase	A	and	B inhibitors
CCI
CCI
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	194.Anticoagulant	 ornonsteroidal	 anti-inflammatory	 drug	(NSAID;	 including	 aspirin)	 use,
when	 patient	 platelet	count	is	<	50	x	109/L
	
5.
Management	of	Study	Toxicities:		
AEintensity	 will	be	evaluated	 using	the	National	 Cancer	 Institute	 (NCI)	Common	 Terminology	
Criteria	for	Adverse	Events	(CTCAE)	version	5,	published	27 -NOV-2017.	 Refer	to	Section	 8.2
for	additional	detail	on	management	of	study	toxicities.
Contact	 the	Medical	 Monitor	 to	discuss	 bomedemstat	 dose	 modifications for	clinically	
significant	 AEchanges	in	platelets,	neutrophil	counts,	or	other	hematologic	parameters.
Stopping	Rules: 		
Bomedemstat	will	be	 permanently	discontinued, and	the	patients	will	undergo	the	Follow -up	
Period	Visits	 (see	Section	 9.4)	in	the	event	of	the	following:
Investigator	 or	Medical	 Monitor	 deem	 it	unsafe	 for	the	patient	 to	continue	 bomedemstat.
Following	 the	temporary	 interruption	 of	bomedemstat	 due	to	platelet	 counts	 below	
the	applicable	threshold	 (25	x	109/L	for	MF	patients	and	50	x	109/L	for	ET	patients ),	the	
patient's	 platelet	 counts	 do	not	return	 to	the	required	 threshold	 (>50	x	109/L	for	MF	
patients	 and	>150	x	109/L	for	ET	patients )within	 21days. Note:		new	platelet	 thresholds	
may	apply	as	additional	 feeder	studies	 are	conducted;	 such	thresholds	 will	be	specified	
in	the	Study	Reference	Manual	and	Pharmacy	Manual.
CCI
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	20Criteria	for	Evaluation :		
The	parameters	comprising	safety	and	efficacy	 assessments are	below.		Details	on	endpoints	
and	data	analysis	are	provided	in	Section s	12.4and	12.5,	respectively.
	
	
	
Safety
In	all	patients ,	safety	will	be	assessed	by:	
Evaluation	of:	
oAdverse	events	(AEs)
oSerious	adverse	events	(SAEs)
oRequired	 laboratory	 tests	(hematology,	 chemistry,	 coagulation	 and	urinalysis)
oPhysical	examinations,	including	vital	signs
Efficacy
In	all	patients ,	efficacy	will	be	assessed	by	evaluation	of:	
Constitutional	 symptoms	 measured	 by	continued	 completion	 of	the	version	 of	the	
MPN-SAF	tool	associated	with	the	feeder	study
Formal	measures	of	response,	including	 relapse,	and	disease	transformation
Fibrosis	 score
In	MF	patients ,	efficacy	will	also	be	assessed	by:
Spleen	volume	reduction	
In	ET	patients ,	efficacy	will	also	be	assessed	by:
Patient	reported	change	in	clinical	status	as	measured	by	the	PGIC
Durability	 in	the	reduction	 of	platelet	 counts	 in	the	absence	 of	new	thromboembolic	
events
Durability	in	the	reduction	of	white	blood	cell	count	
Evaluation	of	 the	incidence	of	thromboembolic	events	
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	213INTRODUCTION
3.1Background	on	the	Disease	to	be	Treated
The	BCR-ABL1-negative	myeloproliferative	neoplasms	(MPNs)	are	a	family	of	related	neoplastic	
disorders	 of	bone	marrow.	 	The	three	main	chronic	 BCR-ABL1-negative	MPNs	 are	polycythemia	
vera	(PV),	 essential	 thrombo cythemia	(ET)	and	primary	 myelofibrosis	 (PMF).	 	The	cardinal	
clinical	features	 of	these	disorders	are	increased	red	cell	mass	in	PV,	increased	platelet	count	in	
ET,	and	bone	marrow	 fibrosis	 in	PMF.		The	MPNs	 are	clonal	 disorders	 arising	 most	frequently	
from	 acquired	 (somatic)	 mutations	 in	a	multipotent	 hematopoi etic	stem/progenitor	 cell,	
resulting	 in	abnormalities	 in	red	cell,	granulocyte	 and	platelet	 production	 often	 in	association	
with	marrow	 fibrosis	 and	extramedullary	 hematopoiesis	 and,	in	some	 cases	 evolution	 to	acute	
myeloid	leukemia	(AML).
3.2Background	on	 theDrug	Target
LSD1,	 also	known	 as	KDM1A,	 is	an	enzyme	 that	removes	 mono-and	dimethyl	 groups	 from	
histone	 (H)	H3	at	critical	 lysines	 (K),	K4	and	K9(Shiet	al.,	2004) .		Methylation	 of	histone	 H3K4	
and	H3K9	 is	a	post-translational	 modification	 associated	 with	changes	 in	the	confirmation	 of	
chromatin	 (Bannister	 and	Kouzarides,	 2011;	 Beisel	 and	Paro,	2011) .		Chromatin	 is	collecti ve	term	
for	the	association of	nuclear	 macromolecules	 consisting	 of	deoxyribonucleic	 acid	(DNA),	protein	
scaffolding,	 enzymes	 enhan cing	transcription	 and	synthesis	 of	ribonucleic	 acid	(RNA)(Kornberg,	
1974).	 	The	DNA	and	its	protein	 scaffold	 of	histones	 form	 anordered	 complex	 called	 the	
nucleosome.	 	Each	nucleosome	 is	composed	 of	two	copies	 of	each	of	the	four	histone	 proteins,	
H2A,	H2B,	H3	and	H4,	forming	 an	octamer	 around	 which	 DNA	is	wrapped.	 	The	rates	of	gene	
transcription	 are	heavily	 influenced	 by	the	accessibility	 of	transcription	 factors	 and	the	RNA	
polymerase	 complexes	 to	template	 DNA	at	promoters	 (Bannister	 and	Kouzarides,	 2011;	Beisel	
and	Paro,	2011) .
Epigenetics	refers	to	the	 regulation	of gene	expression	resulting	from	chemical	modifications	of	
histones,	 the	DNA	bases	 such	as	cytosine	 or	RNA,	 changes	 that	do	not	alter	the	actual	 DNA	
sequence	 (Bird,	 2002).	 	Enzymes	 that	modify	 these	substrates	 by	the	addition	 or	removal	 of	these	
chemical	 changes	 are	called	 epigenetic	 regulators.	 	Histone	 and	nucleic	 acid	modifications	
provide	 binding	 sites	for	proteins	 and	components	 of	the	transcriptional	 machinery	 that	affect	
transcriptional	 gene	silencing	 or	activation	 (Kouzarides,	 2007).	 	Histone	 modific ations	 include	
acetylation	 (Ac),	methylation	 (Me),	 phosphorylation	 (Ph)	and	ubiquitination	 (Ub).		By	virtue	 of	
altering	 the	local	state	of	chromatin,	 LSD1	 is	an	epigenetic	 regulator	 of	gene	expression.	 	The	
primary	 therapeutic	 effects	 of	LSD1	 inhibition	 inthe	treatment	 of	essential	 thrombocythemia	
come	from	the	down	regulation	of	 megakaryopoiesis	and	thrombopoiesis,	functions	that	require	
LSD1	activity.	
LSD1	is	 localized	 to	specific	sites	in	 the	genome	 through	 the	agencies	 of	proteins	 that	bind	DNA	
direct ly,	generally	transcription	factors	(TFs)	 (Whyte et	al.,	2012;	Whyte et	al.,	2013) .		Many	TFs,	
both	activators	such	as	V -Myb	Avian	Myeloblastosis	Viral	Oncogene	Homolog	(MYB)	and	steroid	
hormone	 receptors,	 as	well	as	repressors	 such	as	growth	 factor	 indepe ndence	 1	transcription	
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	22repressor	 (GFI1)	 and	RE-1	silencing	 transcription	 factor	 (REST),	 recruit	 LSD1	to	specific	 genomic	
locations	 (Metzger et	al.,	2005;	 Saleque et	al.,	2007;	 Linet	al.,	2010) .		LSD1	is	part	of	a	larger	
protein	 complex,	 containing,	 e.g.,	Co-RE-1	silencing	 transcription	 factor	 (CoREST)	 or	nucleosome	
remodeling	and	histone	deacetylase	(NuRD),	which	dictates	the	cell -and	site -specific	chromatin	
remodeling (Leeet	al.,	2005;	 Foster et	al.,	2010) .		These	complexes	 may	also	include	 DNA	
methy ltransferase	 1	(DNMT1)	 and	histone	 deacetylases	 1,	2	and	3	(HDAC1,	 2,	and	3)	activities	all	
of	which	 contribute	to	 maintaining	or	 modifying	the	epigenetic	state	at	that	 specific	 genomic	site	
(Shiet	al.,	2005;	 Orkin	 and	Hochedlinger,	 2011) .		Thus,	an	 importan t	property	of	LSD1	beyond	 its	
own	enzymatic	 activity	 is	its	function	 as	a	scaffold	 for	other	 proteins	 and	epigenetic	 enzymes	 that	
are	co-recruited	 to	genomic	 sites.		Likewise,	 LSD1	bound	 to	specific	 sites	precludes	 the	binding	
of	other	factors	that	may	inf luence	transcription.	
LSD1	 is	unique	 among	 the	many	 histone	 demethylases	 in	that	it	coordinates	 flavin	 adenine	
dinucleotide	 (FAD)	 to	oxidatively	 remove	 one	or	two	methyl	 groups,	 in	the	process	 producing	
H2O2and	formaldehyde.		As	such,	FAD	is	an	essential co-factor	for	LSD1	activity (Shiet	al.,	2004) .		
The	other	 34	histone	lysine	demethylases,	collectively	termed	the	Jumonji	demethylases,	employ	
an	iron-dependent	 mechanism	 to	remove	 methyl	 groups	 from	histone	 lysines	 (Klose et	al.,	2006) .	
LSD1is	an	essential	 gene;	 loss	of	LSD1	 activity	 leads	 to	early	embryonic	 lethality (Wang et	al.,	
2009;	 Foster et	al.,	2010) .		The	protein	 is	also	needed	 for	regulating	 the	balance	 between	 self-
renewal	and	proliferation	 (Wang et	al.,	2007) .		A	conditional	 in	vivoLSD1knockdown	(KD)	usin g	
a	doxycycline -inducible	 short	hairpin	 LSD1(shLSD1)	established	 LSD1	 as	a	central	 regulator	 of	
hematopoietic	 stem	cells	(HSCs)	 and	progenitor	 cells	(Sprussel et	al.,	2012) .	An	inducible	 LSD1
KD	resulted	 in	profound	 but	reversible	 thrombocytopenia,	 neutropenia	 and	anemia;	 monocyte	
numbers	were	increased as	monopoiesis	 does	not	require	 LSD1	activity .		LSD1KD	for	27	days	led	
to	an	increase	 in	circulating	 multipotent	 progenitors	 (MPPs)	 and	HSCs	with	a	concomitant	 down-
regulation	 of	chemokine	 (C-X-C	motif)	 receptor	 4	(CXCR4)	 without	 affecting	the	size	of	the	
quiescent	long -term	HSC	pool (Sprussel et	al.,	2012) .		
LSD1	plays	a	key	role	in	regulating	the	progression	from	pluripotency	to	terminal	differentiation	
and	balancing	self -renewal	and	proliferation	 (Adamo et	al.,	2011;	Wang	 et	al.,	2007;	Whyte et	al.,	
2012) .		LSD1	is	recruited	to	“high	confidence”	promoters	and	super -enhancers	of	genes	 essential	
for	normal	 development	 by	the	“master”	 transcription	 factors	 octamer -binding	 transcription	
factor	 4	(OCT4),	 SRY	(sex	determining	 region	 Y)-box2(SOX2),	 Nanog	 and	the	co-activator	
Mediator.	 	Though	 not	essential	 for	maintenance	 of	the	embryonic	stem	 cell	(ESC)	state,	 as	part	
of	the	NuRD	 complex,	 LSD1	 “decommissions”	 enhancers	 of	genes	 maintaining	 the	pluripotency	
program	 allowing	 ESC	to	differen tiate.		LSD1	is	essential	 for	the	complete	 shutdown	 of	the	ESC	
gene	expression	 program	 as	cells	transition	 to	more	differentiated	 cell	states (Whyte et	al.,	2012) .		
The	role	LSD1	plays	in	ESCsis	phenomenologically	 similar	 to	the	essential	 role	LSD1	plays	during	
myeloid	 hematopoiesis,	 in	which	 enhancers	 active	 in	HSCs	 generating	 a	stem-cell	gene	
expression	 signature	 are	also	“decommissioned”,	 allowing	 commitment	 of	progenitors	 to	specific	
myeloid	 lineages (Lara-Astiaso et	al.,	2014) .		Enhancers	 essential	 for	terminal	 myeloid	
differentiation	 in	lineage -specific	 progenitor	 cells,	 the	so-called	 de	novoenhancers,	 must	 be	
poised	 for	activation	 by	the	placement	 of	H3K4me1	 marks.	 	As	progenitors	 commit	 to	
differentiation,	LSD1	is	down -regulated	dramatically	allowi ng	de	novoenhancers	and	promoters	
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	23to	be	stably	 activated	 with	progressive	 methyl	 or	acetyl	 additions	 on	H3K4	 and	H3K27,	
respectively	 (Lara-Astiaso et	al.,	2014) .			
3.3Background	on	LSD1	in	Myeloid	Neoplasia	 Pre-Clinical	Studies
Over-expression	of	 LSD1messenger	RNA	(mRNA)	and	excess	LSD1	protein	have	been	observed	
in	many	 tumor	 types,	 including	 poorly -differentiated	 neuroblastoma,	 squamous	 cell	carcinoma,	
Ewing’s	 sarcoma,	 AML,	 neuroendocrine	 carcinomas	 and	epithelial	 tumors	 such	 as	breast,	
prostate,	 bladder,	 small	cell	lung	and	colon	 cancers	 (Metzger et	al.,	2005;	 Kahlet	al.,	2006;	 Schulte
et	al.,	2009;	Lim et	al.,	2010) .		In	MPN s,	LSD1	was	over -expressed	mainly	in	megakaryocytes	and	
erythroid	 precursors	 and	to	a	lesser	 degree	 inearly	myeloid	 cells	(Niebel	 et	al.,	2014).	Treatment	
of	various	tumor	types	in	culture	with	LSD1	inhibitors	(LSDi)	has	been	reported	to	inhibit	tumor	
growth,	 reduce	 their	 potential	 for	migration	 and	invasion,	 reduce	 clonogenic	 potential	 and	
eliminate	canc er	stem	cells,	induce	 markers	of	differentiation	appropriate	to	the	cell	lineage,	and	
induce	 apoptosis (Somervaille	 and	Cleary,	 2006;	 Somervaille et	al.,	2009;	 Harris et	al.,	2012;	
Zhang et	al.,	2013) .		In	various	 models	 of	mouse	 leukem ia,	treatment	 with	LSD1	inhibitors	
induced	 monocytic	 markers	 of	differentiation,	 reduced	 clonogenic	 potential	 of	leukem ia	
initiating	cells	(LICs),	and	induced	cell	death (Harris et	al.,	2012) .		
LSD1	 activity	 is	present	 in	a	high	proportion	 of	malignant	 myeloid	 blasts	 cells(Linet	al.,	2011;	
Rhodes et	al.,	2007;	 Wouters et	al.,	2009) .		LSD1	gene	expression	 is	among	 the	highest	 in	
immunophenotypically	stem/progenitor	populations	of	myeloid	neoplastic	cells (Goardon et	al.,	
2011; Somervaille et	al.,	2009;	Harris et	al.,	2012) .		
LSD1	may	 play	a	direct	 role	in	regulating	 pathogenic	 signaling	 from	the	activated	 Janus	 Kinases	
(JAK)	signal	transducer	and	activator	of	transcription (STAT)pathway.		The	JAK -STAT	signaling	
pathway	 is	activated	 by	the	canonical	 MPN	 mutations	 in	MPL,	JAK2and	CALRviathe	
phosphorylation	 of	STAT3	 and	STAT5,	 transcription	 factors	 that	activate	 specific	 sets	of	genes	
with	pleiotropic	 effects	 (Chen	 and	Mullally,	 2014).	 	STAT3	 activity	 as	a	transcription	 factor	 is	
modulated	by	methylation	on	lysine	(K140)	and	is	one	of	many	reported	 non-histone	 substrates	
for	LSD1	(Yang	 et	al.,	2010).		
Proof-of-concept	 studies	 of	the	therapeutic	 activity	 of	LSD1	 inhibition	 were	performed	 in	well	
established ,pre-clinical	 mouse	models	 of	MPNs (Jak2V617F,MplW515L).		Compared	 to	mice	treated	
with	vehicle,	 LSD1	 inhibition	 (LSDi)	 in	MPLW515Lmice	markedly	 suppressed	 myeloproliferation	
reducing	 granulocyte	 and	platelet	 counts,	 thus	establishing	 therapeutic	 efficacy .Spleen	 weights	
in	treated	 animals	 showed	 a	dose-proportional	 decrease.	 	Histopathological	 analysis	 of	bone	
marrow	and	spleen	confirmed	a	marked	reduction	in	myeloproliferation,	as	well	as	a	reversal	of	
extramedullary	 hematopoiesis	 (EMH).	 	Most	notably,	 there	 was	near-complete	 resolution	 of	
reticulin	 fibrosis	 in	the	bone	marrow	 in	the	LSDi	treatment	 arm.		LSD1	inhibition	 had	a	significant	
impact	 on	serum	 inflammatory	 cytokine	 concentrations	 as	exemplified	 by	a	very	marked	
reduction	in	the	plasma	concentration	of	the	 Chemokine	(C -X-C	Motif)	Ligand	5 (Cxcl5or	IL-8	in	
humans ),	a	key	participant	in	the	pathologic	inflammatory	state	of	MPN.		
LSD1	 inhibition	 also	reduced	 the	mutant	 cellburden.	 	In	a	mouse	 model	 of	AML	in	which MLL-
AF9hadbeen	virally	 transduced	 into	transplanted	 mouse	 HSCs	along	 with	the	gene	for	green	
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	24fluorescent	 protein (GFP),	 in	those	 mice	treated	 with	vehicle,	74.6%	 of	circulating	 cells	were	
GFP+,	while	 only	43.2%	 of	circulating	 cells	were	 GFP+in	LSDi-treated	mice.	 	Flow	cytometry	
analysis	 of	spleen	 and	bone	marrow	 revealed	 reduced	 numbers	 of	CD11b+/Gr1+myeloid	 cells	
and	CD41+megakaryocytes. The	numbers	 of	mutant	 GFP+	myeloid	 cells	and	megakaryocytes	 in	
these	tissues	were	also	significantly	reduced	by	L SDi	treatment.		The	decrease	in	platelet	count s	
and	mutant	 clone	burden,	 and	the	resolution	 of	fibrosis	 after	28	days	of	LSD1	 inhibition	 supports	
targeting	LSD1	in	patients	with	MPN.
3.4Background	on	 Bomedemstat	(IMG -7289/MK-3543)
Bomedemstat is	an	orally	 available,	 irreversible	 inhibitor	 of	LSD1,	 active	 against	 LSD1	and	human	
AML	cells	at	concentrations	 of	<5	nM.		Irreversible	 inhibitors	 of	LSD1	 include	 tranylcypromine	
(TCP)	 which	 has	been	used	for	the	treatment	 of	depression	 for	decades.	 	The	targets	 of	TCP	
therapy,	however,	include	all	FAD -dependent	monoamine	oxidases	(MAOs)	in	addition	to	LSD1.		
TCP	inactivates	 LSD1	 in	a	manner	 identical	 to	its	action	 on	MAO-A	and	MAO-B	because	 these	
three	enzymes	share	a	similar	oxidative	chemistry.		 Bomedemstat has	>4000 -fold	selectivity	for	
LSD	over	monoamine	oxidase	A	and	B,	the	mostly	closely	related	human	enzymes.		
Pharmacokinetic	 studies	 in	mouse,	 rat	and	dog	and	 pharmacokinetic	 modeling	 in	human	 systems	
suggest	 that	once-daily	dosing	 in	humans	 would	 be	sufficient	 to	achieve	 therapeutic	 exposures .		
Twenty -six	and	thirty-nine	week	 toxicologic	 studies	 in	rat	and	dog,	respectively,	 showed	 that	
	
	
	
	
.
3.5Potential	Clinical	Risks	and	Benefits	when	 Dosing an	LSD1	Inhibitor
The	dosing	 effects	 with	an	LSD1	 inhibitor	 (LSDi)	 are	distinct	 from	treatment	 with	standard	
cytotoxic	agents	or	with	Janus	Kinase	(JA K)cloinhibitors.		
LSD1	 inhibition	 has	specific	 effects	 on	eachmyeloid	 lineage.	 	LSD1	activity	 is	needed	 for	the	
differentiation	of	progenitors	to	red	 cells,	platelets	 and	granulocytes ;LSD1	activity	is	not	needed	
for	monopoiesis.	 	Hence,	LSD1	 inhibition changes	 the	cellular	 composition	 in	the	marrow and	the	
morphology	of	these	cells.	 Likewise,	distribution	of	blood	cells	based	on	lineage	is	also	affected	
with	an	increas ein	the	production	 of	monocytes	 and	a	decreasing	 inthe	other	 myeloid	 cell	types;	
the	production	 of	platelets	 appears	 to	be	more	 sensitive	 to	 LSD1	 inhibition	 and	 red	cell	
production	 the	least.	 	There	 is	no	evidence to	datethat	inhibition	 of	LSD1	 has	an	effect	 on	the	
function	 of	platelets	 or	neutrophils.	 	 	
	
		
The	morphologic	 and	clinical	 pathology	 changes	 may	not	be	familiar	 to	clinicians	 and	
hematopathologists. 		 	
	
CCI
CCI
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	251.
2.
3.
4.
Please	refer	to	the	Investigator’s	Brochure,	Section	6.3	for	Reference	Safety	Information.
3.6Bomedemstat	 Dose	Justification
A	summary	 of	the	starting	 dose	and	dosing	 schedule	 are	provided	 below.	 	Further	 information,	
including	additional	relevant	data,	can	be	found	in	the	Investigator’s	Brochure.
3.6.1 Rationale	for	and	Safety	of	the	Proposed	 Bomedemsta tDose
In	the	Phase	 2study	 in	MF	patients (IMG-7289-CTP-102),	the	daily	dose	of	bomedemstat needed	
by	mostpatients	 to	achieve	 a platelet	 count	 in	the	target	 range	 (50-75x	109/L)	is	between	
0.6to	0.8	mg/kg /dwith	a dosing	spectrum	 investigated	 of0.4-1.5	mg/kg /d.		
Inthe	Phase	 2	study	 in	ETpatients	 (IMG-7289-CTP-201),	the	daily	dose	of	bomedemstat	 needed	
to	reduce	 platelet countsinto	the	target	 range	 (200-400	x	109/L)	is	alsocurrently	 between	
0.6to	0.8	mg/kg/d. 		
CCI
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	26To	date,	f or	both	patient	populations evaluated	 in	clinical	studies IMG-7289-CTP-102	and	 -201,	
the	dose sneeded	to	reduce	the	platelet	count	to	the	target	range	 do	not	appear to	be	correlated	
with	the	starting	platelet	count	or	antecedent	hematologic	history.		
In	thePhase	 1	studyin	high-risk	AML/ myelodysplastic	 syndrome	 (MDS)patients (IMG-7289-
CTP-101),	therewas	no	 maximum	tolerated	dose	observed	 with	doses	up	to 6	mg/kg/d.		
Patients	enter ingthis	study	 will	have	received	bomedemstat	for	at	least	6	months	in	their	feeder	
study.	 	All	patients	 will	be	dosed	 with	bomedemstat	 daily	in	the	extension	 study,	 with	dose-
titration	contingent	on	the	Titration	Assessment	performed	at	every	 TP	visit.		Patients	receivi ng	
their	first	extension	 study	 dose	with	no	interruption	 in	dosing will	have	a	Titration Assessment	
performed	at	 the	Transition	 Visit	to	determine	 if	a	titration	 is	needed.	 	Patients	 requir ingan	
interruption	 in	dosing	 will	have	a	Titration	 Assessment	 performed	 at	the	Transition	 Visit	to	
determine	 if	they	will	commence	 at	the	same	 daily	doseof	bomedemstat being	 taken	 at	the	
conclusion	 of	their	feeder	 study or	if	a	down- titration	 or	dose	hold	is	needed	 (up-titrations	 are	
not	permitted) .		
The	dose	of	bomede mstat needed	 to	reduce	 platelets	 to	the	applicable	 target	 range	 is	anticipated	
to	be	up	to	approximately	 2	mg/kg	 once	daily	(QD);	however,	 this	is	not	the	upper	 limit	for	
titration	 purposes	 as	the	dose	needed	 to	achieve	 a	therapeutic	 effect	 will	vary	among patients	
and	may	change	over	time.		The	upper	 limit	for	titration	purposes	is	6	mg/kg/d	( note: this	dose	
cannot	be	exceeded	during	the	dose	titration	process).		
3.6.2 Rationale	for	the	 Bomedemstat Dosing	Schedule
This	is	an	open-label	extension	 study	 that	intends	 tocontinue	 to	dosepatients with	bomedems tat
for	as	long	as	they	are	safely	 tolerating	 and	receiving	 clinical	 benefit	 from	its	use.	Patients	
entering	 this	study	 will	have	received	 bomedemstat	 for	at	least	6	months	 in	theirpriorfeeder	
study.	 	Dose-titration	 will	continue	 to	be	contingent	 on	the	hematology	 assessments ,	specifically: 		
platelets,	 hemoglobin	 and	absolute	neutrophil	 count	 (ANC).		Titration	 targets	 and	rules,	 including	
the	frequency	 with	which	 up-and	down- titrations	 are	permitted,	 andthe	associated	 titration	
increments/decrements	 are	specific	 to	the	underlying	 MPN	 and	are	detailed	 in	the	Study	
Reference	Manual	and	Pharmacy	Manual.		
Chronic	 daily	administration	 of	bomedemstat in	rat,	dog	and	humans	 has	beenwell	tolerated.	 	No	
safety	 signals ,	per	Safety	 Advisory	 Board reviews	 to	date,	have	been	observed	 in	either	 the	
AML/MDS ,myelofibrosis ,	oressential	 thrombocythemia	 studies	 with	bomedemstat at	doses	 up	
to	6	mg/kg/d and	for .
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	274HYPOTHESIS AND OBJECTIVES
Hypothesis :	Bomedemstat is	safe	 and	tolerable	 when	 administered long-termto	patients	 with	
MPNs ;	inhibition	 of	LSD1	by	bomedemstat will	provide	 long-termclinical	 benefit	 topatients with	
MPNs.
4.1Objectives
The	objectives	of	this	extension	study	are	to: 		
Continue	 to	assess	 the	safety,	 tolerability	 and	efficacy	 ofbomedemstat	 in	patients	 who	
received	bomedemstat	in	a	prior	study
Measure	 the	extent	 and	durability	 of	bomedemstat	 treatment	 effects	 on	exploratory	
endpoints	including	any	impact	of	bomedemstat	on	the	natural	history	of	MF	and	ET
5INVESTIGATIONAL PLAN
5.1Overview
This	is	a	Phase	 2	multi-center,	 open-label	extension	 study	 for	patients	 with	myeloproliferative	
neoplasms dosed	with	bomedemstat	 in	a	prior	clinical	study .			
This	study	consists	of	Treatment	Period s(TP)	w here	patients	will	be	treated	daily	for	169	days.		
The	TPs	are	iterative andtreatment	 may	continue	 for	an	additional	 169	days	in	those	 patients	
deriving	 clinical	 benefit	 (defined	 as	not	meeting	 “progressive	 disease ”criteria	 as	per	applicable	
Appendix 16.4or16.5)and	safely	 tolerating	 bomedemstat, as	determined	 by	theInvestigator;	
this	definition	applies	throughout	the	document	and	will	not	be	repeated	with	each	reference	to	
clinical	benefit.	
Eligibility	 criteria	 will	be	assessed	 based	 on	the	patient’s	 final	visit	in	their	feeder	 study.	 	 	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
CCI
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	28
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	296STUDY POPULATION
6.1Study	Entry	Criteria
For	purposes	of	eligibility,	the	following	definitions	apply:
A	woman	 is	considered	 of	childbearing	 potential	 (WOCBP),	 i.e.,fertile,	 following	
menarche	 and	until	becoming	 post-menopausal	 unless	 permanently	 sterile.	 Permanent	
sterilisation	 methods	 include	 hysterectomy,	 bilateral	 salpingectomy	 and	bilateral	
oophorectomy.	
A	postmenopausal	 state	 is	defined	 as	no	menses	 for	12	months	without	 an	alternative	
medical	cause.	 A	high	follicle	 stimulating	 hormone	 (FSH)	 level	in	the	postmenopausal	
range	 may	be	used	to	confirm	 a	post-menopausal	 state	 in	women	 not	using	 hormonal	
contraception	or	hormonal	replacement	therapy.	However,	in	the	 absence	of	12	months	
of	amenorrhoea,	a	single	FSH	measurement	is	insufficient.	
A	man	 is	considered	 fertile	 after	 puberty	 unless	 permanently	 sterile	 by	bilateral	
orchidectomy.
Abstinence	 is	defined	 as	refraining	 from	heterosexual	 intercourse. 		True	abstine nce,	when	
this	is	in	line	with	the	preferred	 and	usual	 lifestyle	 of	the	subject	 is	permitted.	 Periodic	
abstinence	 (e.g.,	calendar,	ovulation,	 symptothermal,	 post-ovulation	 methods),	 declaration	 of	
abstinence	for	the	duration	of	 the	Treatment	and	Follow- up	Period s,	and	withdrawal are	not	
acceptable	methods	of	contraception.
6.1.1 Inclusion	Criteria
Patients	must	meet	 allof	criteria	to	be	eligible	for	 study	 enrollment:
1.Completed	 at	least	one	Treatment	 Period	 (TP)	in	 a	prior	 bomedemstat	 MPN	protocol	 (such
as,	but	not	limited	to,	 IMG-7289-CTP-102	or	IMG -7289-CTP-201).
2.In	the	estimation	 of	the	Investigator,	 the	risk-benefit	 favors	 continued	 dosing with	
bomedemstat .		
6.1.2 Exclusion	Criteria
Patients	will	be	excluded	from	the	study	if	they	meet	 anyof	the	following	criteria:
1.Ongoing	participation	in	another	investigational	study	(except	observational	studies) .
2.A	history	 of	non-compliance	 in	a	prior	bomedemstat	 study	 (excluding	 dose	suspensions that	
were	medically	warranted).
3.Current	use	of	a	prohibited	medication	(e.g.,	romiplostim).
4.Medical,	 psychiatric,	 cognitive,	 or	other	 conditions	 that,	in	the	Investigator’s	 opinion,	
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	30compromise	 the	patient’s	 safety,	 ability	 to	give	informed	 consent,	 or	comply	with	the	trial	
protocol .
5.Females	who	are	pregnant	or	breastfeeding	or	plan	to	become	pregnant	or	breastfeed	during	
the	study.
6. 	
	
	
	
	
	
	
	
		
6.2Patient	Enrollment
This	study	will	enroll	 approximately 80	patients	 with	an	MPN	that	 meet	the	eligibility	criteria .			
6.3Patient	Withdrawal
In	accordance	 with	the	Declaration	 of	Helsinki,	 Good	 Clinical	 Practice	 (GCP),	 and	International	
Council forHarmoni sation	(ICH)	 Guidelines	 and	applicable	 regulations	 governing	 human	 subject	
protection,	 a	subject	has	the	right	to	withdraw	 from	the	study	 at	any	time	for	any	reason.	 The
patient’s reason	 for	withdrawal,	 if	given,	 will	be	documented	 in	the	electronic	 case	report	 form	
(eCRF).		Patients	 will	be	requested	 to	complete	 theFollow-up	Period	 visits	for	post-dosing	 safety	
assessments	 as	per	Section 9.4.		
Subjects	 may	also	be	removed	 from	the	study	 by	the	Sponsor	 or	Investigator.	 The	Sponsor	 or	
Investigator	may	remo ve	patients	from	the	study	for	various	reasons,	including:	
Taking	another	investigational	medicinal	agent	during	the	study ;
Use	of	a	prohibited	medication;
Major	violation	 of,	or	deviation	 from,	study	protocol	 procedures	 which,	 in	the	judgment	 of	the	
Medical	Monitor,	 could	 adversely	 affect	 the	patient	 or	the	integrity	 of	the	study	 includin g	
missing	 an	extended	 duration	 ofbomedemstat doses	 or	other	 evidence of	major	 non-
compliance;	
Withdrawal	from	the	study	is,	in	the	Investigator’s	judgment,	in	the	 patient’s	best	interest.
6.4Patient	Care	 Guidelines
Patient	 safety	 is	paramount.	 The	patient	 care	guidelines	 below	 are	intended	 to	facilitate some	
consistency	across	sites	by	providing	guidance	to	be	used	by	the	Investigator and	the	study	staff	Note:		In	the	UK,	male patient s	with	a	pregnant	partner	must	agree	to	use	a	condom	to	avoid	
exposure	to	the	developing	child.		
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	31to	ensure	 patient	safety and	recognize	 the	standard	 of	care	across	 global	 institutions	 will	vary.		
The	guidelines	 are	not	protocol	 requirements	 and	are	not	intended	 to	supersede	 best	clinical	
judgment	by	the	Investigator.		Please	contact	the	Medical	Monitor	with	 any	que stions.
For	all	patients :
1.In	general,	supportive	 care	 (transfusions,	 administration	 of	anti-fungals,	 etc.)	should	 be	
maintained	 in	accordance	 with	institutional	 policy. 		(Note:	 	Transfusions	 must	be	adequately	
recorded	 in	the	source	 documents	 to	facilitate data	entry	 of	the	study	 required	 parameters	
[i.e.,	type	of	blood	product	transfused,	units,	total	volume ]).
2.Patients	 taking	 medications	 with	the	potential	 to	induce	 or	inhibit	 CYP3A4	 or	CYP2D6	
should	 be	monitored	 closely	 for	potential	 effects	 of	co-administration;	 particular	 attention	
should	be	given	to	anti -infectives	in	the	azole class.
3.There	 are	no	restrictions	 to,	or	recommendations	 on	the	timing	 of,	administration	 of	
vaccines	(i.e.,	COVID -19	vaccination).
4.Cessation	 of	bomedemstat	 is	associate d	with	a	rebound	 in	thrombopoiesis ,and	platelet	
counts may	exceed	baseline	in	 thepatient.	 When	bomedemstat	is	discontinued,	platelet	
counts mustbe	monitored	closely	and	the	timing	of	the	start	of	an	alternative	 therapy	
should	take	 the	expected	rebound	of	platelets	into	 consideration .		

5.
6.5Prohibited	Medications
Please	consult	the	Medical	Monitor	with	any	questions	pertaining	to	prohibited	medications.	
1.All	cytotoxic agents	with	noted	exception	 of	hydroxyurea	 for	MF	patients	as	per	 Guidelines
2.All	hematopoietic	 growth	 factors:	 romiplostim, eltrombopag,	 granulocyte	 and	granulocyte -
macrophage	colony	stimulating	factor	(G- CSF	and	GM -CSF)	and	erythropoietin	(EPO)
3.Monoamine	oxidase	A	and	B inhibitors
4.Anticoagulant	or nonsteroidal	anti -inflammatory	drug	( NSAID;	including	aspirin)	use ,when
patients	platelet	count	is	<	50	x	109/L
CCI
CCI
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	32For	MF	patients only:
5.Prednisone orprednisolone >10mg/day or	dexamethasone	 >	4	mg/day	 (doses	 exceeding	
these	 thresholds	 are	permitted formanagement ofgout).	 Maintenance supplemental	
corticosteroid	 therapy	 such	as	prednisone	 ≤	10	mg/day	 or	corticosteroid	 equivalent	 is
allowed.
7STUDY PRODUCT
7.1Formulation,	Labeling,	Packaging	and	Storage
7.1.1 Formulation
Thedrug	product bomedemstat	 (IMG-7289 /	MK-3543)isa	bis-tosylate	 salt.		The	free	base	of	
bomedemstat is	the	active	moiety.		
Bomedemstat will	be	supplied	 in	capsules	 of	multiple strengths .		These	strengths arebased	 on	
bomedemstat free	base(the	active	 substance ).		Thestrengths	 may	change	 over	the	duration	of	
the	study.	 	Detailson	capsules	 strengths ,	colours and	sizes,	can	be	found in	the	Pharmacy	 Manual. 		
The	capsules	will	be	manufactured	in	accordance	with	Annex 13	and	principles	of	 cGMP.
7.1.2 Packaging	and	Labeling
Bomedemstat capsules	 will	be	supplied	 to	the	site	pharmacy	 department	 by	sponsor (or	
designee)	in packaging	in accordance	with	all	applicable localregulatory	requirements.	
Packaging	l abels	will	 also	be	in	accordance	with	all	applicable	 local	regulatory	 requirements	for	
the	labeling	 of	active	 pharmaceutical	 ingredients	 and	with	Annex 13	of	cGMP.		Labels	will	contain	
the	drug	name,	protocol	number,	lot	number,	 expiry date,	storage	conditions ,	name	of	the	 (local)
Sponsor and	a	caution	that	the	 investigational	 drugproduct is	forclinical	 trialuse	only.
7.1.3 Storage
The	recommended	long -term	storage	condition	for	 bomedemstat is	atemperature not	to	exceed	
25°C.Bomedemstat must	be	stored	 in	a	secure	 area	with	access	 limited	 to	the	Investigator	 and	
authorized	 staff	and	under	 the	physical	 conditions	 that	are	consistent	 with	bomedemstat -specific	
requirements. 		Bomedemstat supplies	 will	be	stored	 securely	 under	 the	appropriate	 conditions	
according	to	the	country,	 state	and	regional	 laws.	 Procedures	 for	bomedemstat storage	 and	
accountability	will	be	detailed	in	a	 Pharmacy	 Manual.
7.2Dispensing,	Administration,	Dosage	and	Missed	Doses
7.2.1 Dispensing
All	material	 supplied	 is	for	use	only	in	this	clinica l	study	 and	should	 not	be	used	for	any	other	
purpose.	 	Only	patients	 enrolled	 in	the	study	 may	receive	 bomedemstat ,	in	accordance	 with	all	
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	33applicable	regulatory	requirements.	Only	authorized	site	staff	may	 dispense bomedemstat .
The	Investigator	 must	 provid e	a	prescription	 form	 every	 time	bomedemstat	 isdispensed,	
including	 (but	not	 limited	 to)	the	identification	 of	the	patient	 to	whom	 bomedemstat	 is	to	be	
dispensed,	 the	patient’s	 weight,	 the	requested	 dose	 in	mg/kg/d and	the	Investigator	 (or	
designee’s) signature.	
Bomedemstat will	be	dispensed at	doses in	accordance	 with	the	dose	chart	 provided and	at	the	
quantities	 detailed	 in	the	Pharmacy	 Manual .		Since	 the	bomedemstat dose	and	associated	 capsule	
strengths	 for	each	patient may	change	 over	time,	minimize	 the	patient	 retaining	 excess	 study	
drug	capsules in	their	home.
Patients	will	be	instructed	to	bring	 any	unused bomedemstat	in	its	dispensed	 packaging to	each	
study	 visit	for	drug	accountability.	 	New	bomedemstat	 supply will	be	dispensed	 at	each	visit.		The	
Investigator	and	designated	staff	will	maintain	study	drug	accountability	records	( Section	 14.5).
7.2.2 Administration
Appropriately trained	 study	 site	personnel	 will	provide	 patient	 instruction spertaining	 to	
bomedemstat administration	and	 supervise	 the	administ ration	 ofbomedemstat, iftaken	 in	the	
clinic.		It	is,	however, not	required	 that	bomedemstat be	taken	 in	the	clinic;	 this	will	be	
determined	based	on	the	patient’s	regular	daily	dosing	time.		When	applicable,	the	date	and	time	
of	each	administration	in	the	clinic	will	be	recorded	in	the	source	notes.
Bomedemstat dosing	will	be	based	on	the	patient’s established Dosing Weightfrom	their	 feeder	
study.		If	during	treatment	 the	patient’s	weight	 changes	by	more	than	10% from	the	established	
Dosing	 Weight, the	amount	 of	bomedemstat dispensed	 should	 be	adjusted per	the	dose	chart.
The	dispensing	 prescription	 form	and	source	 data	must	clearly	 document	 the	weight	 usedto	
calculate	the	dispensed	daily	dose .
Patients	should	be	instructed	to:
Swallow	the	bomedemstat capsule(s) once	daily,	at	approximately	the	same	time .		
oWhile	it	would	be	 recommended	to	take	a tnight	before	bed,	dose	can	be	taken	at	
any	time	during	the	day	when	convenient .
Swallow	the	bomedemstat capsule(s) whole .
Fast	for1	hour	prior	to	and	 30	minutes after	a	daily	dose.	
Clear	liquids	 are	allowed	during	the	fasting	peri od.
7.2.3 Dosage		
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	347.2.4 Missed	Doses
Patients	 whodo	not	take	their	bomedemstat dose	at	the	usual	 required	 time	should	 take	it	
immediately	 upon	noting	 that	it	was	not	taken;	 the	patient	 should	 not	take	the	dose	more	 than	
12	hours	 after	the	usual	 dosing	 time.		If	a	patient	misses	 a	dose,	they	should	not	 take	two	doses	
the	following	da y,	but	should	notify	their	study	coordinator	and	continue	with	their	normal	daily	
dose	the	following	 day.		For	atemporary dosing	 interruption due	to	amedical	 or	unforeseen	
patient	situation ,	please	consult	the	Medical	Monitor	for	guidance	on	re -start	of	 dosing.		Patients	
who	miss	an	extended	 duration	 of	bomedemstat doses	 or	exhibit	 serial	 non-compliance	 with	
treatment	may	be	removed	from	the	study	at	the	discretion	of	the	 Investigator	or	 Sponsor.
7.2.5 Interruption	of	Dosing
Patients	 requiring	 a	Dose	Hold	accor ding	to	the	Titration	 and	Rechallenge	 Rules,	due	to	an	(S)AE,
or	other	unforeseen	 patient	 situation	 that	interrupts	 daily	dosing	 should	 undergo	 complete	 blood	
counts at	least	weekly	 for	safety	 purposes	 and	to	enable	 re-challenge	 to	commence	 as	soon	as	
counts	return	to	the	required	level ,	if	itissafe	to	do	so .	
8SAFETY ADVISORY BOARD (SAB ) REVIEWS AND MANAGEMENT OF 
STUDY TOXICITIES , INCLUDING STOPPING RULES
8.1Safety	 Advisory	Board (SAB)	Reviews
Safety	 will	be	monitored	 throughout	 the	study	in	 accordance	 with	a	Safety	Advisory	 Board	 Plan	
(SABP)	by	a	SAB	constituted	 byphysicians	 with	hematology	 expertise	 and	clinical	 study	
experience .		SAB	reviews	 will	occur	 at	least	quarterly	 as	perthe	SABP.	Reviews	may	 also	occur	
on	an	ad	hoc basis	when	one	of	the	 following	scenarios	occurs:
Fatal	or	life-threatening	 reaction	 assessed	as	 related	to	 bomedemstat (possibly,	 probably	
or	definitely),	regardless	of	expectedness,	is reported
Occurrence	 of	other	 safety -related	 issues	 for	patient s	receiving	 bomedemstat,	 such	as	
evidence	 of	unexpectedly	 severe	 effects	 on	hematopoiesis,	 which	 pose	a	medical	 concern ,
and	which	may	necessitate	 bomedemstat dose	adjustment	or discontinuation.
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	35SAB	responsibilities	will	remain	in	effect	until	the	study	has	ended.
8.2Management	of	Study	Toxicities
Expected	 bomedemstat toxicities	 based	 on	non-clinical	 and	clinical	 studies	 are	reported	 in	the	
latest	available	edition	of	the	Investigator’s	Brochure.		
AEintensity	 will	be	evaluated	 using	 the	National	 Cancer	 Institute	 (NCI)	 Common	 Terminology	
Criteria	for	Adverse	Events	(CTCAE)	version	 5,	published	27 -NOV-2017.
Stopping	rules	are	defined	in	Section	 8.2.2.		
8.2.1 Hematologic	Toxicity
Hematologic	values	outside	of	the	normal	reference	range	are	inherent	features	of	MPNs	and	are	
expected	 effects	 of	many	therapeutic	 attempts	 to	manage	 these	 diseases.	 MPNpatients	 require	
doses	 of	bomedemstat	 that	are	sufficient	 to	reduce	 platelet	 counts	 and,	to	a	lesser	 degree,	
absolute	 neutrophil	 counts.	 	Any	resulting reversible	 cytopenias	 can	be	managed	 clinically	 as	
needed	with	transfusions	as	well	as	broad -spectr um	antibiotics,	as	 perstandard	practice.	
The	effects	 of	bomedemstat on	normal	 myeloid	 hematopoiesis	 observed	 in	non-clinical	 and	
clinical	 studies	 are	expected;	 these	 are	pharmacodynamic	 effects	 of	LSD1	 inhibition	 by	
bomedemstat ,	thus	not	regarded	as	adve rse.		Refer	to	 the	Investigator’s	 Brochure for	additional	
information.
8.2.2 Stopping	Rules
Bomedemstat will	be	permanently	 discontinued	 and	the	patients	 will	undergo the	Follow -up	
Period	visits (see	Section	 9.4)	in	the	event	of	the	following:
PI	or	Medical	Monitor	deem	it	unsafe	for	the	patient	to	continue	bomedemstat.	
Following	 thetemporary	 interruption	 of	bomedemstat due	to	platelet	 counts	 below the	
applicable	 threshold	 (25	x	109/L	for	MF	patients	 and	50	x	109/L	for	ET	patients ),the	patient's	
platelet	 counts	 do	not	return	 to	the	required	 threshold	 (>50	x	109/L	for	MF	patients	 and	>150	
x	109/L	for	ET	patients )within	 21	days.		Note:	 new	platelet	 thresholds	 may	apply	 as	
additional	 feeder	 studies	 are	conducted;	 such	thresholds will	be	specified	 in	the	Study	
Reference	Manual	and	Pharmacy	Manual.
9STUDY ASSESSMENTS 
This	section	 provides	 comprehensive	 detail	 on	the	visits	 and	assessments	 required andshould	
serve	 as	the	main	guidance	 for	use	during	 study	 visits.		The	Schedule	 of	Assessments	 (Section	
16.1)	contains	 these	 details	 in	tabular	 form	and	is	provided	 for	use	in	asupport ive/reference
capacity	only .		Tomaintain	clarity	while	facilitating	a	modicum	of	brevity,	the	 ‘Terms’	in Table	 1
below	will	be	utilize d	in	this	section	to	encompass	the	broader	‘Protocol	Meaning’	as	stated.
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	36Table	 1 List	of	Protocol	 Terms and	Meanings
Term Protocol	Meaning
Limited	 Physical	 Exam,	 including	
Vital	SignsSpleen	measurement .	The	edge	of	the	 spleen	shall	be	
determined	 by	palpation,	 measured	 in	centimeters,	
using	a	soft	ruler/tape,	from	the	costal	margin	to	the	
point	 of	greatest	 splenic	 protrusion in	the	mid-
clavicular	 line.		Measure	 in	the	same	 manner	 at	all	
visits.
Weight,	measured	(in	kg)
Review	 of	body	systems	 for	changes	 from	previous	
visit	
Vital	signs,	 after	patient	 has	sat	semi-supine	 for	~3	
minutes,	of:
oHeart	rate
oRespiratory	rate
oTemperature
oSystolic/diastolic	blood	pressure
Adverse	 Events	 and	Concomitant	
Medications	CollectionUse	non-directive	 questions	 (i.e.,	“How	 are	you	feeling”)	
to	query	 patient	 regarding	 AEs	that	may	have	occurred	
and	inquire	about	medication	changes.
Full	Local	Lab	Assessment The	following	 panels	 performed	 locally	 (Section	 10.1.1
details analytes):
Hematology	with	automated	differential
Biochemistry
Coagulation
Urinalysis
Serum	pregnancy	test	for	WOCBP
MPN	Symptom	 Questionnaires IRB/EC	 approved	 questionnaires will	be	completed	
based	 on	the	version required	 inthe	applicable feeder	
study.		For	example ,	the	MPN-SAF	TSS	for	IMG-7289-CTP-
102	and	the	MPN -SAF	for	IMG -7289-CTP-201.
Questionnaires will	be	completed	 weekly ,	ideally	 at	the	
same	 time	and	day	each	week	 for	consistency, through	
the	EoSor	ETVisit.	 	The	actual	 date	of	questionnaire	
completion ,	not	the	planned	 or	collected	 date,must be	
documented	 on	each	questionnaire	 completed.	 On	visit	
days,	the	 questionnaire should	be	completed	prior	to	the	
study	 visit.If	the	patient	 arrives	 without	 a	completed	
questionnaire ,	the	patient	 will	complete	 it	during	 the	
visit,and	it	will	be	collected by	study	 staffprior	 to	the	
patient	departing.		
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	37Term Protocol	Meaning
Importantly,	 multiple	 question naireswill	need	 to	be	
provided	to	the	patient	for	completion	 on	a	weekly	basis	
between	 visits.	 	Note,	 for	patients	 undergoing	 monthly	
labs	locally,	consideration	should	be	given	to	the	use	of	a	
courier	for	 provision	and	return	of	 questionnaires.
Bone	 Marrow	 Sampling and	
AssessmentsAspirate	sample	should	be	optimally	obtained	within	
the	first	pull.	Do	not	collect	 after	 a	second	 pull	
attempt ,and	biopsy	 collected	 as	per	site	standard	
procedure.		
A	central	 laboratory	 will	perform	 morphology	
review ,fibrosis	 grading	 and	store	 BMMC sfor	
possible	 correlative	 research	 analysis (Section	
10.1.2 ).		
Note:	 	Any	results	 available	 from	site	routine	 bone
marrow	 work-up,	 including	 morphology,	
cytogenetics,	 other	 genetic	 interrogations	 will	be	
collected	either	via	the	eCRF	or	through	collection	of	
local	reports.
Study	Drug	Dispensing	and	 Dosing	
InstructionsAdminister	 bomedemstat	 in	accordance	 with	 the	
Pharmacy	Manual	instructions .
Instruct	 patients	 to	refer	to	their	Dosing	 Card	every	
day	for	details	 on	bomedemstat dosing	 (Section	 7.2.2)	
and	handling	of	missed	doses (Section	 7.2.4)
Note:	 	If	at	any	time	additional	 clinical	evaluation	 outside	 of	the	visit	schedule	 is	deemed	
necessary	 by	the	Investigator,	 then	unscheduled	 visits	should occur,and	datashould	 becollected .
9.1Enrollment	Period
9.1.1 Informed	Consent	 Visit
Details	 of	the	extension	 study	 and	a	copy	of	the	Participant	 Information	 Sheet/Consent	 Form
(PISCF)	 should	 be	provided	 to	the	patient	 prior	 to	their	anticipated	 final	feeder	 study	 visit.		
Informed	 consent	 should	 be	obtained	 at,	or	before,	 the	feeder	 study’ s	final	visit.		Patients	 must	
provide	 document edinformed	 consent	 before	 undergoing	 any	study-related	 procedures.	 The	PI,	
or	designee,	 will	explain	 to	the	patient	 the	study purpose ,	the	risks	and	benefits	 involved	 and	that	
their	participation	 is	voluntary .		Each	patient	 will	acknowledge	 receipt	 of	this	information	 and	
that	they	wish	to	participate in	the	study	 by	giving	 documented informed	 consent	 for	their	
involvement	 in	the	study	 in	the	presence	 of	the	PI,	or	designee,	 who	will	also	sign	and	date	the
PISCF.	Time,	date,	name	 of	the	person	 taking	 consent	 and	any	questions	 raised	 by	the	patient	
mustbe	documented	in	the	source	data.
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	389.1.2 Eligibility	Assessment
Once	 consent	 has	been	obtained	 for	participation	 in	the	extension	 study,	 the	PI	will	assess	
whether	 the	patient	 is	eligible.	 	If	the	patient	 meetsall	eligibility	 criteria,	 thenthey	will	be	
enrolled	 upon	commencement	 of	their	first	extension	 study	 visit	(Section 9.1.4).		Patients	 deemed	
ineligible	 should	 have	 the	reason( s)documented	 in	the	patient’s	 source	 data	and	on	the	
Screening	&	Enrollment	log.
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	39
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	40
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	41
CCI
08WYVV
Page	42
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	43
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	44
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	45
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	4610LABORATORY SAMPLING FOR SAFETY AND PD ANALYSIS
Blood,	bone	 marrow	and/or	their	contents	may	be	retained	for	future	exploratory	studies.
The	average	 of	the	blood	 volumes collected ,	which	 varies	 by	local	laboratory	 institution,	 is	
provided	 in	EC/IRB	approved	the	informed	consent .	
See	Section	10.1	and	10.2	for	the	s pecifics	and	volumes	required	for	each	test.			
10.1Laboratory	Measures
Details	 on	the	laboratory	 assessments performed	 throughout	 the	study	 are	provided	 below	 by	
category	 of	tests	 (i.e.,	biochemistry,	 hematology,	 etc.).		Details	 on	the	specific	 laboratory	
assessments	 required	 at	each	visit	 are	located	 in	Section	 9and	in	schematic	 form	in	Appendix	
16.1.		When	each	category	 of	test	is	required,	 at	a	minimum,	 the	following	 clinical	 laboratory	
determinations	 (or	their	equivalent)	 will	be	performed.	 	Exceptions	 are	noted	 by	asterisk	 (*)	to	
reflect	 thatthe	particular	 analyte	 will	only	be	analysed	 if	the	test	is	available	 at	the	particular	
institution.		
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	4710.1.1 Local	Laboratory	Measures
Biochemistry :	Serum	 creatinine,	 uric	acid,	urea*	 or	blood	 urea	nitrogen	 (BUN)*,	 albumin,	 total	
bilirubin,	 gamma	 glutamyltransf erase	 (GGT),	 alkaline	 phosphatase	 (ALP),	 alanine	
aminotransferase	 (ALT),	 aspartate	 transaminase	 (AST),	 lactate	 dehydrogenase	 (LDH) ,	C-reactive	
protein	(CRP)	and	serum	ferritin .
Hematology:	Hemoglobin,	 red	blood	 cell	count	 (RBC)	 (including	 nucleated	 RBC),	 red	cell	
distribution	 width, hematocrit,	 mean	 corpuscular volume	 (MCV),	 mean	 corpuscular haemoglobin	
(MCH),	 mean	 corpuscular haemoglobin	 concentration	 (MCHC),	 platelets,	 mean	 platelet	 volume	
(MPV)*,	white	cell	 count and	automated	 or	manual	 assessment	 as	needed	 to	ensure	 the	following	
results	 are	generated :neutrophils,	 lymphocytes,	 monocytes,	 eosinophils ,	basophils ,	
reticulocytes ,promyelocytes,	myelocytes,	metamyelocytes	 and	blasts. 		
Coagulation :	Prothrombin	 time	 (PT)*,	activated	 partial	 thromboplastin	 time	 (aPTT)	 and	
International	normalized	ratio	( INR).
SerumPregnancy	 Test:	For	WOCBP,	 a	serum	 pregnancy	 test	will	be	utilized	 according	 to	
institution	 standard	 procedure .		The	result	 must	be	confirmed	 prior	to	next	scheduled	 dose	of	
bomedemstat .		
Urinalysis :	Leucocyte	 esterase,	 nitrites,	 urobilinogen,	 protein,	 pH,	blood,	 specific	 gravity,	
ketones,	bilirubin	and	glucose.
Bone	marrow	 sampling:	 	At	each	sample	 time-point	both	aspirate	 (unless	 there	is	a	dry	tap)	and	
biopsy	 sample s	arerequired	 to	be	obtained	 as	per	site	standard	 procedure.	 Evaluation	 of	
morphology	 including	 fibrosis	 score	 will	be	performed	 centrally	 (see	Section	 10.1.2 );.		
Additionally ,any	locally	 available	 cytogenetic	 or	genetic	 interrogations	 performed	 on	samples	
obtained	 at	the	same	time-point	 as	study	samples	will	 also	be	reported	 in	the	eCRF	or	collected	
vialocal	lab	reports.		
Additional Tests for Italy:   HIV test, HAV, HBsAg, HBsAb, HBcAb, HCV
Sample	Processing :	Sponsor will	not	provide	 either	 a	laboratory	 manual	 or	study	 supplies	 for	
the	collection	 and	handling	 of	samples	 to	be	analysed	 locally.	 	Local	laboratory	 standard	
procedures	should	be	followed	at	each	site.
Blood	sample	volume:	 The	volume	 of	blood needed	 to	perform	a	Full	Local	 Laboratory
Assessment and	a	Hematology	Local	Laboratory	Assessment varies	by	institution .
10.1.2 Central	Laboratory	Measures
Bone	Marrow	Sampling	 Requirements: 		Approximately	 2-3	mL	bone	marrow	 aspirate	 sample	
for	central	 analysis	 must	be	collected	 from	the	first	pull,	whenever	 possible,	 and	no	later	than	the	
second	(except	 in	the	case	of	dry	tap).		A	 peripheral	 blood	 smear	 must	also	be	 provided	 the	same	
day	forreview	in	conjunction	with	the	 bone	marrow	sample ;	additionally	a	de -identified	copy	of	
the	hematology	 (CBC)	 report	 from	the	day	of	bone	marrow	 sampling	 should	 be	sent	to	the	central	
lab	with	the	bone	marrow	samples	(or	follow	by	email	as	soon	as	availabl e).		A	1-2	cm	section	of	
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	48trephine	 bone	marrow	 sample	must	 also	be	collected and	 sent	to	the	central	 laboratory	 as	a	
formalin	 fixed,	paraffin	 embedded	 block	(unless	 alternative	 arrangements	 have	been	agreed	 with	
sponsor ).		Measures	 to	be	performed	 centrally include:	 myelofibrosis	 grading	 and	morphology	
review.	 	Remaining bone	marrow	 aspirate	 following	 preparation	 of	the	morphology	 slides	 may	
be	used	for	analysis	 of	mutant	 allele	burden	 over	the	course	 of	bomedemstat treatment.	 	Genomic	
sample	 collection,	 handling,	 storage,	 and	analysis	 will	conform	 to	all	applicable	 national	 guidance	
and	regulations .
Genomic	 Testing:	 	At	each	required	 sample	 time-point	 approximately	 20	mLperipheral blood	
sample	 will	be	collected	for	analysis.		 During	the	feeder	protocols germline	 samples consisting of	
hair	roots	and	a	cheek	 swab	werecollected	 for	analysis.	 	If,	upon	analysis,	 the	sample	 yield	was	
found	 to	be	inadequate	 a	repeat	sample	 of	either	 type	may	be	requested as	part	of	their	feeder	
study	or	as	part	of	this	protocol .	Genomic	sample	collection,	handling,	storage,	and	analysis	will	
conform	to	all	applicable	national	guidance	and	regulations.		
Future	Correlative	Studies: 		Approximately	 10	mL	additional	blood	will	be	collected	 and	stored	
in	conjunction	 with	each	genomic	 blood	 sampling	 time-point	 for	the	purposes	 of	potential	
correlative	studies.		If	site	process	permits,	samples	collected	and	stored	earlier	in	the	course	of	
their	MPN,	and	any	available	genetic	data	may	be	requested. 		
Patients	at	specific	sites/countries	may	need	to	provide	specific	consent	for	the	analysis	of	these	
correlative	 samples but	samples	 will	be	collected	for	all	patients .	
Sample	Processing :	Sponsor will	provide a	laboratory	 manual	 documenting	 the	collection	 and	
handling	 of	samples	 to	be	analysed	 centrally.	 	Laboratory	 supplies	 will	be	provided	 for	the	
collection	of	all	central	laboratory	samples.
11SAFETY
The	Investigator	is	responsible	for	monitoring	the	safety	of	patients	enrolled	in	this	study.		
Ifthe	patient	is	withdrawn	 from	treatment,	 the	patient	 will	discontinue	 study	 treatment	 and	on	
that	day	or	as	soon	as	possible	 thereafter	 undergo	 an	EoT	visit	and	have	the	Follow-up	Period	
EoS	visit	scheduled (see	Section	 9.4).		
11.1Pregnancy	
	
	
	
	
	
	
	
	
	
	
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	49	
	
	
	
	
	
		
	
	
11.2Adverse	Eve nts	
The	Investigator	 is	responsible	 for	monitoring	 the	safety	 of	patients	 who	have	enrolled	 in	the	
study	 and	for	accurately	 documenting	 and	reporting	 information	 as	described	 in	this	section.
Patients	 will	be	instructed	 to	report	 to	the	Investigator	 any	AE	that	they	experience.	 	Investigators	
will	ask	about	 the	occurrence	 of	AEs	at	each	 visit.		Investigators	 are	required	 to	document	 all	AEs	
occurring	 during	 the	clinical	 study,	 commencing	 with	the	first	dose	of	bomedemstat at	the	
Transition	Visit	 through	to the	EoSVisit	(scheduled	at	 14	days	post	last	 bomedemstat dose).		 AE
recording	will	 continue	for	patients	who	discontinue	study	 drug	but	remain	in	 Follow-upPeriod ,	
until	their	 EoTand	EoSVisits	have	been	completed. 		
Note:	 Any	medical	 event	 i.e.,(S)AE	 which	 is	ongoing	 from	the	feeder	 protocol	 study	 at	the	time	of
dosing	 with	bomedemstat in	this	protocol	 must	be	documented	 in	the	patient’s	 medical	 notes	 and	
will	be	recorded	on	the	appropriate	eCRF	pages as	AEs	ongoing	 at	the	time	of	study	entry .	
New	AEs	will	be	recorded	 on	designated	 eCRF	pages.	 Each	AE	is	to	be	characterised	 (i.e.,	verbatim	
term)	 and	information	 provided	 regarding	 its	seriousness,	 start	 and	stop	dates,	 intensity,	
outcome,	and	causal	relationship	with the	study	drug .	
An	AE	is	any	undesirable	 physical,	 psychological	 or	behavioral	 effect	 experienced	 by	a	patient	
during	 participation	 in	an	investigational	 study,	 in	conjunction	 with	the	use	of	the	drug	or	
biologic,	 whether	 or	not	product -related.	 	This	includes	 any	untoward	 signs	 or	symptoms	
experienced	 by	the	patient	 from	the	time	of	first	dose	with	bomedemstat	 under	 this	protocol until	
completion	of	the	study.
AEs	may	include,	but	are	not	limited	to:
Subjective	 or	objective	 symptoms	 spontaneously	 offered by	the	patient	 and/or	
observed	by	the	Investigator	or	medical	staff
Findings	at	physical	examinations
Laboratory	abnormalities	of	clinical	significance
Overdose	defined	as	any	dose	exceeding	the	prescribed	dose	for	 bomedemstat
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	50Potential	 DILI	events	 define d	as	an	elevated	 AST	or	ALT	laboratory	 value	 that	is	
greater	 than	or	equal	 to	3×	the	ULN	and	an	elevated	 total	bilirubin	 laboratory	
value	that	is	greater	 than	or	equal	 to	2×	the	ULN	and,	at	the	same	time,	an	alkaline	
phosphatase	laboratory	value	that	is	le ss	than	2×	the	ULN,	as	determined	by	way	
of	protocol -specified	laboratory	testing	or	unscheduled	laboratory	testing.
It	is	important	 Investigators	 record	 accurate	 AE	terms	 in	the	eCRFs.	 	Wherever	 possible,	 a	specific	
disease	or	 syndrome	 rather	than	 individ ual	associated	signs,	 symptoms	 or	laboratory	parameter	
will	be	identified	 by	the	Investigator	 and	recorded	 in	the	eCRF.	 	However,	 if	an	observed	 or	
reported	 sign,	symptom	 or	laboratory	 parameter	 is	not	considered	 a	component	 of	a	specific	
disease	or	syndro me	by	the	Investigator,	or	is	atypical,	it	should	be	recorded	as	a	separate	AE	in	
the	eCRF.
Disease	 signs,	 symptoms,	 and/or	 laboratory	 abnormalities	 already	 existing	 prior	to	the	use	of	the	
study	 drugare	notconsidered	 AEs	after	treatment	 unless they	reoccur	after	the	patient	 has	
recovered	 from	the	preexisting	 condition	 or	in	the	opinion	 of	the	Investigator	 they	represent	 a	
clinically	significant	exacerbation	in	intensity	or	frequency. 		
Clinical	 significance	 is	defined	 as	any	variation	 in	signs,	 symptoms, or	testing	 that	has	medical	
relevance	 and	may	result	 in	an	alteration	 in	medical	 care.		The	Investigator	 will	continue	 to	
monitor	the	patient	until	the	assessment	returns	to	Baseline	or	until	the	Investigator	determines	
that	follow -up	is	no	longer	medical ly	necessary.
11.2.1 Adverse	Event	Intensity
AEintensity	 will	be	evaluated	 using	 the	NCI	CTCAE	 version	 5,	published	 27-NOV-2017.	For	AEs	
not	included	 in	the	NCI	CTCAE,	 the	Investigator	 will	be	required	 to	assess	 the	intensity	 of	the	
adverse	drug/biologic	experience	using	the	following	categories	and	associated	guidelines:		
Grade Guideline
1 Mild;	 asymptomatic	 or	mild	symptoms;	 clinical	 or	diagnostic	 observations	 only;	
intervention	not	indicated
2 Moderate;	 minimal,	 local	 or	noninvasive	 intervention	 indicated;	 limiting	 age-
appropriate	instrumental	ADL*
3 Severe	 or	medically	 significant	 but	not	immediately	 life-threatening;	 hospitalization	
or	prolongation	of	hospitalization	indicated;	disabling;	limiting	self -care	ADL**
4 Life-threatening	consequences;	urgent	intervention	indicated
5 Death	related	to	AE
Note	1:	A	semi -colon	indicates	‘or’	within	the	descr iption	of	the	grade.
Note	2:	Activities	of	Daily	Living	(ADL)	
*Instrumental	 ADL	refer	 to	preparing	 meals,	 shopping	 for	groceries	 or	clothes,	 using	 the	telephone,	
managing	money,	etc.
**Self-care	ADL	refer	to	bathing,	 dressing	 and	undressing,	 feeding	 self,using	 the	toilet,	 taking	
medications,	and	not	bedridden.
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	5111.2.2 Adverse	Event	Relatedness
The	Investigator	will	make	a	judgment	regarding	whether	or	not,	in	his/her	opinion,	the	AE	was	
related	 to	study	 drug.		The	Investigator	 will	also	evaluate	 any	changes	 in	laboratory	 values,	 make	
a	determination	 as	to	whether	 the	change	 is	clinically	 significant,	 and	whether	 or	not	the	
change(s)	 were	 related	 to	study	 drug.	 	However,	 even	if	the	Investigator	 feels	there	 is	no	
relationship	 to	the	study	 drug,	 the	AE	or	clinically significant	 laboratory	 abnormality	 MUST be	
recorded	in	the	eCRF.		Below	are	guidelines	for	relationship	assessment:
Unrelated:	There	was	no	relationship	of	the	 AEto	the	use	of	the	drug	or	biologic.	This	
may	include,	but	is	not	limited,	to	the	adverse	experience	being	an	expected	outcome	
of	a	previously	existing	or	concurrent	disease,	concomitant	medication	or	procedure	
the	subject	experienced	during	their	treatmen t	period.	
Remote/Unlikely:	 AEs	which	are	judged	probably	not	related	to	the	drug	or	biologic.	
Possible:	There	was	no	clear	relationship	of	the	 AEto	the	use	of	the	drug	or	biologic;	
however,	one	cannot	definitively	conclude	that	there	was	no	relationship .
Probable:	 While	 a	clear	relationship	 to	the	drug	or	biologic	 cannot	 be	established,	 the	
event	 is	associated	 with	an	expected	 AE(per	the	current	 Investigator	 Brochure	 or	
SAB	findings)	 or	there	 is	no	other	 medical	 condition	 or	intervention	 which	 would	
explain	the	occurrence	of	such	an	experience.	
Definite:	 The	relationship	 of	the	use	of	the	drug	or	biologic	 to	the	experience	 is	
considered	definitively	established.
If	a	causal	 relationship	 is	considered	 probable,	 possible,	 or	definite	 by	the	Investigator or	Sponsor	
(dependent	 on	the	regional	 reporting	 requirements) ,	the	AE	is	considered	 to	be	“related”	 for	
purposes	 of	regulatory	 reporting.	 If	a	causal	 relationship	 is	considered	 remote/unlikely	 or	
unrelated,	the	AE	is	considered	“unrelated”	for	purposes	of	r egulatory	reporting.		
11.2.3 Serious	Adverse	Events
SAEs	will	be	reportable	from	the	time	of	first	dose inthe	extension	study through	the	 EoSor	ET
Visit	oruntil	the	Investigator	 and	sponsor determine	 that	follow -up	is	no	longer	 necessary.	 	SAEs	
that	are	suspected	to	be	drug	related	 will	be	reported	 even	if	they	occur	 when	 the	patient	 is	no	
longer	on	the	study.		
An	SAE	is	any	AE	that	results	in	any	of	the	following	outcomes:
Death
Life-threatening	 experience .	Any	AEthat	places	 the	patient,	 in	the	view	of	the	reporter,	 at	
immediate	 risk	of	death	 from	the	AEas	it	occurred,	 i.e.,	does	not	include	 an	AEthat	had	it	occurred	
in	a	more	severe	form,	might	have	caused	death.
Required	 or	prolonged	 inpatient	 hospitaliz ation¥.	The	AEresulted	 in	an	initial	 inpatient	
hospitaliz ation	or	prolonged	an	existing	 hospitaliz ation	of	the	patient.	If	a	patient	is	 hospitaliz ed	
as	part	of	the	clinical	 use	of	the	product,	 a	period	 of	normal	 hospitaliz ation	will	be	outlined	 in	the	
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	52protocol	 or	by	the	judgment	 of	the	Investigator.	 Hospitaliz ations	 longer	 than	this	period	 will	be	
prolonged	 hospitaliz ations.
Persistent	or	significant	disability/incapacity .	An	AEthat	resulted	in	a	substantial	disruption	
of	a	person’s	ability	to	conduct	normal	life	funct ions.
Congenital	Anomaly. The	exposure	of	the	patient	to	the	drug	or	biologic	during	pregnancy	that	
is	judged	to	have	resulted	in	the	congenital	anomaly/birth	defect.
Important	 medical	 events .	AEs	that	may	not	result	 in	death,	 be	life-threatening,	 or	require	
hospitaliz ation	may	be	considered	 anSAEwhen,	 based	 upon	appropriate	medical	judgment,	may	
jeopardise	 the	patient	 or	subject	 and	may	require	 medical	 or	surgical	 intervention	 to	prevent	 one	
of	the	outcomes	 listed	 above.	 Important	 medical	 events	 orinterventions	 may	be	considered	 an	
SAE	based	upon	medical	judgment of	the	Investigator.		
11.2.4 Reporting	Serious	Adverse	Events	
SAEs	will	be	reported	 promptly,	 using	 the	SAE	Report	 Form,	 once	the	Investigator	 determines	
that	the	event	meets	 the	protocol	 definition	 of	an	SAE.	 	The	Investigator	 or	designee	 will	report	
the	SAE	within	 24	hours	 of	his/her	 becoming	 aware	 of	these	 events	 regardless	 of	
relationship	 of	the	SAE	to	the	use	of	study	 drug,	in	accordance	 with	the	instructions	 in	the	
Study	 Reference	 Manual .	The	Investigator	 will	always	 provide	 an	assessment	 of	relatedness	 at	
the	time	of	the	initial	 report	 as	described	 in	Section	 11.2.2 .		The	SAE	Report	 will	always	 be	
completed	as	thoroughly	as	possible	with	all	available	details	of	the	event	within	the	designated	
time	frames .	Copies	 of	relevant	 patient	 records,	 autopsy	 reports,	 and	other	 documents	 may	be	
requested.		
If	the	Investigator	 does	not	have	all	information	regarding	an	SAE,	he/she	will	not	wait	to	receive	
additional	 information	 before	 reporting	 the	SAE.	The	SAE	Report	will	be	updated	 when	 additional	
information	is	received	 within	24	hours	of	receipt	of	such	information .
Important: 		For	fatal	and	life-threatening	 events,	 the	event	 should	 be	reported	 in	the	EDC	system	
immediately	 or	within	 24	hours	 of	learning	 of	the	event.		A	death	occurring	 during	 the	study	 or	
information	related	to	such	occurrence	that	comes	to	the	attention	of	the	Investigator	during	the	
study	 must	be	reported	 immediately	 to	the	Sponsor.	 	Adetailed	 SAE	reporting	 procedure and	
contact	 informati onwillbe	included	 in	the	Study	 Reference	 Manual	 (SRM) and	provided	 to	the	
sitebefore	any	patients	are	consented.
Additionally,	 the	Institutional	 Review	 Board	 (IRB),	 Independent	 Ethics	 Committee	 (IEC)	and	
Human	 Research	 Ethics	 Committee	 (HREC),	 as	applic able,	must	be	notified	 in	writing	 of	any	SAEs	
that	require	 expedited	 reporting	 to	Regulatory	 Authorities.	 	Depending	 upon	 regional	
requirements,	 it	is	the	responsibility	 of	the	Investigator	 to	notify	 the	IRB/IEC/HREC.	 	All	SAEs	
meeting	 expedited	 reporting	 requirements	 will	be	reported	 to	appropriate	 regulatory	 agencies	
by	sponsor or	their	designee	 as	soon	as	possible	 and	within	 the	timeframes	 specified	 in	the	
various	regions	in	which	the	study	is	to	be	conducted.
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	5311.2.5 For	Participant sWho	Consent	To	Another	Bom edemstat	Extension	Study
All	AEs,	SAEs,	and	other	reportable	safety	events	must	be	reported	by	the	investigator	in	this	
protocol	up	to	the	time	of	consenting	into	another	bomedemstat	extension	trial.	Laboratory	
values	that	meet	criteria	for	reporting	as	AE s	performed	during	this	study	will	be	collected	in	
this	study.
Note:	Once	consented	to	another	extension	study,	AEs/SAEs	and	other	reportable	safety	events	
meeting	the	reporting	criteria	of	the	extension	study,	including	those	considered	related	to	
study	i ntervention,	will	be	collected	in	the	extension	study.
12ANALYSIS AND STATISTICAL CONSIDERATIONS
12.1General	Considerations
Detailed	methodology	for	summary	and	statistical	analyses	of	the	data	collected	in	this	trial	will	
be	documented	 in	a	Statistical	 Analysis Plan	(SAP).	 	Thisdocument	 may	modify	 the	plans	outlined	
in	the	protocol;	however,	 any	major	modifications	 of	the	primary	endpoint	definition sand/or	its	
analysis	 will	also	be	reflected	 in	a	protocol	 amendment.	 	Additional	 statistical	 analyses	 other	 than	
those	 described	 in	this	section	 may	be	performed	if	 deemed	 appropriate	 and	included	 in	the	SAP.
12.2Power
There	 are	no	sample	 size	calculations	 for	this	extension	 study.	 	Sample	 size	will	be	based	 on	
elective	participation	of	patients	who	were	enrolled	into	th e	feeder	studies.
12.3Treatment	Assignment	and	Blinding
This	is	an	open-label	study.	 	The	Investigators,	 other	 hospital	 personnel,	 patients	 and	Sponsor	
will	know	the	identity	of	the	treatment.		
Effort	 will	be	made,	 as	appropriate,	 to	maintain	 continuity	 of	study	staff	who	administer/evaluate	
various	 assessments	 at	each	site	(i.e.,	physical	 examination,	 morphology/fibrosis	 grade	 review,	
etc.),	in	order	to	facilitate	consistency	of	assessments	within	a	patient.
12.4Study	Endpoints
12.4.1 Primary	 Endpoints
The	safety	 and	tolerability	 of	bomedemstat will	be	assessed	 by	the	analysis	 of	adverse	 events	
(AEs),	 as	well	as	changes	 in	physical	 examinations,	 vital	signs	and	laboratory	 values	 as	detailed	
below.	
Monitoring	 of	Adverse	Events	(AEs),	 serious	adverse	events	(SAEs),	and	AEs.		AEs	will	be	
assessed	 from	time	of	entry	 into	study until	EoSor	ETin	terms	 of	onset,	 duration,	
seriousness,	 severity	 and	causality,	 using	 the	National	 Cancer	 Institute	 Common	
Terminology	Criteria	for	Adverse	Events	(NCI	CTCAE),	Version	 5.		
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	54Changes	in	physical	examinations,	vital	signs	and	laboratory	values	will	also	be	assessed	
until	EoSor	ET.		Information	 on	the	timing	of	these	 assessments	 is	presented	 in	the	
schedule	of	assessment s.		The	following	laboratory	tests	will	be	conducted:
oComplete	blood	counts	(CBC)	and	differential
oCoagulation
oChemistry	
oUrinalysis	
Additionally,	in	 MF	patients:
Spleen	volume	reduction	wil l	be	assessed	based	on	spleen	volume	measured	by	MRI	(or	
CT	where	applicable)	approximately	every	48	weeks.	
Additionally,	i n	ET	patients:
Reduction	 of	platelet	 counts	 will	be	evaluated	 and	assessed	 based	 on	local	laboratory	
measurements	of	platelet	counts collected	serially	throughout	the	study.
12.4.2 Exploratory	 Endpoints
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	5512.5 Data	Analysis
12.5.1 Safety	and	Tolerability	Data Analysis
Demographics	will	be	tabulated	 and	summarized.	 Adverse	 events/ongoing	 medical	event data	at	
the	time	of	study	entry	 will	be	listed,	as	will	P hysical	 Examination	 data	at	time	of	study	 entry,	and	
at	subsequent	 visits.		All	characteristics	 at	baseline	 such	as	age,	weight,	 height	 and	vital	signs	
(resting	 heart	 rate,	 semi-supine	 systolic/diastolic	 blood	 pressure,	 respiratory	 rate	and	
temperature)	pa rameters	 will	be	tabulated	 and	summarized.
All	patients	receiving	at	least	one	dose	of	 bomedemstat will	be	included	in	the	safety	analysis.		
Laboratory	values	 outside	 the	laboratory	 normal	 ranges	 will	be	summarized	 and	assessed	 for	
change	from	 time	of	study	entry	and	 Day	1	in	the	feeder	study .
Treatment -emergent	 adverse	 events	 will	be	coded	 using	 the	Medical	 Dictionary	 for	Regulatory	
Activities	 (MedDRA)	 and	summarized	 for	the	number	 of	patients	 reporting	 the	AE	and	the	
number	 of	AEs	reported.	 	A	by-patient	 AE	data	listing	 including	 (but	not	limited	to)	verbatim	
term,	coded	term,	severity,	and	relationship	to	treatment	will	be	provided.	
Concomitant	 medications	 will	be	listed	 by	patient	 and	coded	 using	 the	WHO	 drug	dictionary.		
Medical	history	will	be	listed	by	patient.
Descriptive	 statistics	 (arithmetic	 mean,	 standard	 deviation	 (SD),	sample	 size,	CV	(coefficient	 of	
variation),	 median,	 minimum,	 maximum,	 and	number)	 will	be	calculated	 for	quantitative	 safety	
data	as	well	as	for	the	differences	 to	baseline and	time	of	study	 entry,when	 appropriate.	 	In	
addition,	 a	shift	table	describing	 out	of	normal	 range	 shifts	 will	be	provided	 for	clinical	 laboratory	
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	56results	 and	physical	 examination	 results.	 	For	safety	 and	tolerability,	 missing	 data	including	 those	
not	obtained	because	of	death	will	be	the	last	va lue	carried	forward.
12.5.2 Efficacy Data	Analysis
The	primary	 efficacy	 objective	 for	this	study	 is	to	measure	 the	extent	 and	durability	 of	
bomedemstat	 treatment	 effects on	the	exploratory	 endpoints	 including	 any	impact	 of	
bomedemstat	 on	the	natural	 history	 of	MFand	ET.		The	long-term	effects	 of	bomedemstat	 will	be	
examined	 by	summarizing	 the	exploratory endpoints	 from	feeder study	 baseline	 through	 the	
extension	study.
If	applicable,	progression	free	survival	(PFS),	event	free	survival (EFS),	and	overall	survival	(OS)	
will	be	calculated	using	the	Kaplan -Meier	method.
Additionally ,for	MFPatients ,	spleen	volume	reduction	will	be	assessed	based	on	spleen	volume	
measured	by	MRI	(or	CT	where	applicable).	
Additionally ,for	ETPatients ,	the	below	 endpoints,	 proportions	 and	corresponding	 95%	
confidence	interval s	will	be	 based	on	the	Clopper -Pearson	method :
CCI
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	5713STUDY ADMINISTRATION
The	names,	 titles,	 and	addresses	 of	the	Investigators	 and	study	 personnel	 are	available	 from	
sponsor .
13.1 Ethical	Considerations
This	research	 will	be	carried	 outin	accordance	 with	the	protocol,	 US	Code	of	Federal	 Regulations,	
GCP,	21	CFR	Parts	50,	56,	and	312,	the	ethical	principles	set	forth	in	the	Declaration	of	Helsinki,	
and	the	ICH	harmonized	 tripartite	 guideline	 regarding	 GCP	(E6	Consolidated	 Guidance,	 April
1996).
13.2Participation	Information	Sheet/Consent	Form	(PISCF)
A	sample	PISCF	document	will	be	provided	to	each	site.		No	major	deviations	may	be	made	from	
the	sample	 PISCF	 other	 than	country -or	region -specific	 formatting	 or	legal	requirements.		
Sponsor andits	advisors	 will	review	 the	site-specific	 draft	PISCF	 before	 it	is	finalised,	 and	the	
final	IRB/I EC/HREC -approved	document	must	be	provided	to	 sponsor for	regulatory	purposes.
The	PISCF	 must	be	documented	 by	the	patient	 before	 his	or	her	participation	 inthe	study.	 	A	copy	
of	the	PISCF	must	be	provided	to	the	patient.		If	required	by	local	procedure	a	second	original	of	
the	PISCF	 may	be	provided	 to	the	 patient.	 	If	applicable,	 it	will	be	provided	 in	a	certified	
translation	of	the	local	language.
An	origin al	signed	 PISCF	 must	 remain	 in	each	patient’s	 study	 file	and	must	 be	available	 for	
verification	by	study	monitors	at	any	time.
13.3Institutional	Review	Board	(IRB),	 Independent	 Ethics	Committee	( IEC)	and	Human	
Research	Ethics	Committee	(HREC)
This	protocol,	th e	PISCF,	relevant	supporting	information	and	all	types	of	patient	recruitment	or	
advertisement	 information	 must	 be	submitted	 to	IRB/IEC/HREC	 for	review	 and	must	 be	
approved	before	the	study	is	initiated.		Any	amendments	to	the	protocol	must	also	be	approve d,	
where	necessary,	by	the	IRB/ IEC/HREC	prior	to	implementing	changes	in	the	study.
The	Investigator	 is	responsible	 for	keeping	 the	IRB/IEC/HREC	 apprised	 of	the	progress	 of	the	
study	 and	of	any	changes	 made	 to	the	protocol	 as	deemed	 appropriate,	 but	in	any	case,	at	least	
once	a	year.		The	Investigator	must	also	keep	the	IRB/ IEC/HREC	informed	of	any	AEs,	according	
to	the	IRB/I EC/HREC	policy.
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	5813.4Study	or	Site	Termination
	
If	Sponsor,	 an	Investigator,	 or	regulatory	 authorities	discover	 conditions	 during	 the	study	 that	
indicate	 that	the	study	 or	related	 activities	 at	a	particular	 site	should	 be	terminated,	 this	action	
may	be	taken	 after	appropriate	consultation	 between	 Spons or	and	the	Investigator.	 	 	
Study	or	site	termination	and	fol low-up	will	be	performed	in	compliance	with	the	conditions	set	
forth	 in	21	Code	 of	Federal	 Regulations	 (CFR)	 Section	 312	and/or	 other	 national	 and	local	
regulations,	 as	applicable,	 and	in	compliance	 with	the	principles	set	 forth	in	ICHGCPs,	 including	
ICH	E6,	and	ethical	principles	established	by	the	Declaration	of	Helsinki.
13.5Study	Monitoring	Requirements
Monitoring	 and	auditing	 procedures	 developed	 by	sponsor will	be	followed	 in	order	 to	comply	
with	ICH	GCP	guidelines.	 	On-site	checking	 of	the	eCRFs	 for	completeness	 and	clarity,	 cross	
checking	 with	source	 documents,	 and	clarification	 of	administrative	 matters	 will	be	performed,	
when	 possible .		Additionally,	 off-site	or	‘remote’	 monitoring	 visits	may	 be	conducted	 as	needed .		
Remote	 monitoring	 may	consist	 of	centralized	 monitoring	 or	remote	 data	review.	 Centralized	
monitoring	is	t he	remote,	cross -functional	review	and	evaluation	of	accumulating	 in-house	 data	
conducted	 by	data	managers,	 central	 monitor	 associate s,	medical	 directors,	 the	clinical	 team,	 and	
biostat isticians.	 The	 review	 of	data	within	 and	across	 sites	proactively	 identifies	 missing	 or	
inconsistent	 data,	data	trends,	 systematic	 or	significant	 errors	 and	enables	 site	performance	
characteristics	 to	be	analyzed.	 Remote	 data	review	 is	intended	 to	encompas s	as	many	 activities	
performed	 in	a	routine	 on-site	monitoring	 visit	as	 is	functionally	 possible,	 and	as	permitted	 by	
site	policy	 and	procedure.	 	The	remote	 review	 of	data	may	be	actioned	 viamultiple	 pathways,	
often	 contingent	 on	site’s	 capabilities.	 	Remote	data	review,	 specifically,	 has	become	 critically	
important	in	the	COVID- 19	environment	as	a	measure	of	 safeguard ingpatient	safety,	while	also	
minimizing	 risks	to	trial	data	integrity	 and	facilitat ing	GCP	compliance .		Note:	 Remot e	data	review	
will	onlybe	implemented	 in	Germany	 in	times	of	increased	safety	 measures	such	as	 the	COVID -
19	pandemic	 and	only	in	special	 cases.		Please	 see	Section	 16.9for	additional	 information	
pertaining	to	remote	data	review.	
Monitoring	visits	will	consist	of	periodic	visits	during	the	study	period	and	site	close -out	visits.		
CCI
CCI
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	59The	Investigator	 will	permit	 authorised	 representatives	 of	sponsor and	the	respective	 national	
or	local	authorities	to	inspect	facilities	and	records	relevant	to	this	study.
Sponsor or	its	designee	 will	monitor	 the	study.	 	Monitoring	 will	be	done	 by	visits	 from	
representatives	 of	sponsor (monitors)	 who	will	review	 the	eCRFs	 and	source	 documents .		The	
monitors	 will	ensure	 that	the	investigation	 is	conducted	 according	 to	protocol	 design	 and	
regulatory	 requirements	 by	frequent	 communications	 (letter,	 email,	 telephone,	 and	fax).The	
monitor/representative	 of	sponsor will	perform	 an	Investigator	 SiteFile	review	 to	confirm	 all	
documents	required	to	reconstruct	the	conduct	of	the	clinical	trial	are	present.		The	 Investigator	
Site	Filesupports	 the	validity	 of	the	research,	 as	well	as	the	conduct	 and	integrity	 of	the	data	
collected,	 and	needs	 to	be	maintained	 by	the	Investigator	 (or	designee)	 and	inspection	 ready	 at	
all	times.	
All	unused	study	materials	are	to	be	returned	to	 sponsor or	its	designee	after	the	clinical	period	
of	the	trial	has	been	completed,	 or	be	disposed	 of	at	the	site	according	 to	institutional	 policies	 but	
not	prior	to	the	approval	of	the	Sponsor	and	with	appropriate	documentation.		
13.6Quality	Assurance
The	study	will	be	initiated	and	conducted	under	the	sponsorship	of	 sponsor .		Bomedemstat and	
clinical	supplies	will	be	supplied	by	 spons or.		Representatives	of	 sponsor will	monitor	the	study	
to	verify	study	data,	medical	records,	worksheets,	and	eCRFs	are	in	accordance	with	current	ICH	
GCPs	and	the	respective	local	and	national	government	regulations	and	guidelines.
The	Investigator	will	c ontact	the	Sponsor	immediately	if	contacted	by	a	regulatory	agency	about	
an	inspection	 at	his	or	her	center.	 The	purpose	 of	Sponsor	audit	or	 inspection	 is	to	systematically	
and	independently	 examine	 all	study-related	 activities	 and	documents	 to	determine	 whether	
these	 activities	 were	 conducted,	 and	data	were	 recorded,	 analyzed,	 and	accurately	 reported	
according	to	the	protocol,	ICH/GCP	guidelines,	and	any	applicable	regulatory	requirements.
13.7Confidentiality
The	information	obtained	during	the	conduct	of	this clinical	study	is	confidential,	and	disclosure	
to	third	parties	other	than	those	noted	below	is	prohibited.
The	patient’s	 identifying	 information	 will	not	leave	the	clinical	 site	at	which	 they	are	recruited.		
The	patient	will	be	identified	on	all	study	do cumentation	using	a	code	number	and	their	initials	
(where	it	is	lawful	to	collect	such	information).
Information	 obtained	 during	 the	conduct	 of	this	study	 will	be	collected,	 processed,	 and	
transmitted	 to	or	for	the	benefit	 of	sponsor in	accordance	 with	theapplicable	 regulations	 and	
principles	 of	confidentiality	 for	each	participating	 country.	 	Information	 contained	 therein	 will	
be	maintained	 in	accordance	 with	applicable	 law	protecting	 patient	 privacy,	 including	 the	
provisions	 of	46	CFR	Part	164	promulgate d	under	 the	Health	 Insurance	 Portability	 and	
Accountability	 Act	(HIPAA)	 and	may	be	inspected	 by	the	clinical	 researcher,	 the	researcher’s	 staff,	
Sponsor	 and	its	representatives,	 partners,	 advisors,	 affiliates,	 successors,	 and	clinical	 research	
contractors	 and	subcontractors	 to	check,	 process,	 evaluate,	 and	use	the	information	 collected	
during	 the	study.	 	The	patient	 PISCF	 (or	a	separate	 data	protection	 consent	 form	if	required	
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	60locally)	 will	be	used	to	obtain	 participant	 consent	 to	authorise	 transfer	 and	processing	 of	data	
consistent	 with	applicable	 law.		Processing,	 evaluation,	 or	use	of	the	information	 will	be	
performed	 by	a	health	 professional	 for	medical	 purposes	 and/or	 by	those	 operating	 under	 a	duty	
of	confidentiality	 that	is	equivalent	 to	that	of	a	health	professional.	 	Information	 obtained	 from	
the	study	 will	likely	 be	used	by	sponsor or	its	affiliates	 or	successors	 in	connection	 with	the	
development	 of	study	 drug,	 including	 possible	 filing	 of	applications	 with	 governmental	
authorities	 for	marketing	 approval,	 and	for	other	pharmaceutical	 and	medical	 research	 purposes.		
The	study	 Investigator	 is	obliged	 to	provide	 Sponsor	 with	complete	 test	results	 and	all	data	
developed	 in	this	study.	 	This	information	 may	be	disclosed	 to	other	 physicians	 who	are	
conduc ting	similar	 studies	 and	to	the	applicable	 regulatory	 authorities	 as	deemed	 necessary	 by	
sponsor .		Patient-specific	 information	 may	be	provided	 to	other	 appropriate	 medical	 personnel	
only	with	the	patient’s	permission,	as	necessary	and	in	accordance	with	o ther	applicable	privacy	
laws	and	regulations	protecting	patient	health	information.	
To	ensure	 compliance	 with	the	ICH	GCP	guidelines,	 data	generated	 by	this	study	 must	be	available	
for	inspection	upon	request	by	representatives	of	the	appropriate	national	and	local	authorities,	
sponsor ,	and	the	IRB/ IEC/HREC	for	each	study	site.
The	raw	dataset	will	be	available	 to	sponsor on	completion	 of	the	study.	 	Sponsor will	actively	
pursue	publication	of	the	results	of	the	study	in	cooperation	with	the	Lead	Investigators	subject	
to	the	terms	 and	conditions	 of	the	clinical	 trial	agreement	 between	 sponsorand	Investigators.		
The	Lead/Coordinating	 Investigator	 will	have	the	right	to	submit	 for	publication	 any	results	
arising	 from	the	study	 subject	 to	the	terms	 and	conditions	 of	the	Clinical	 Trial	and	Confidentiality	
Disclosure	 Agreements.	 	The	Lead/Coord inating	 Investigator,	 with	the	agreement	 of	sponsor ,	will	
coordinate	the	principal	publication	of	the	data	arising	from	the	study.		Patient	names	and	other	
personal	 data	relating	 to	an	identified	 or	identifiable	 patient	 (such	 as	photographs,	 audio,	
videota pes,	or	other	 factors	 specific	 to	physical,	 physiological,	 mental,	 economic,	 cultural,	 or	
social	 identity),	 may	not	be	disclosed	 in	any	publication	 without	 prior	written	 authorisation,	 in	
compliance	with	 patient	privacy	law,	 from	sponsor and	the	patient.
14INVESTIGATOR REQUIREMENTS
14.1Protocol	Adherence
Each	Investigator	 must	adhere	 to	the	protocol	 as	detailed	 in	this	document	 and	agrees	 that	any	
changes	 to	the	protocol	 must	 be	approved	 by	sponsor ’sauthorised	 representative	 in	writing	
prior	to	seeking	 approval,	 where	 necessary,	 from	the	IRB/IEC/HREC.	 	Each	Investigator	 will	be	
responsible	 for	allowing	 only	those	 patients	 who	have	met	all	protocol	 eligibility	 criteria	 to	be	
enrolled.	
Modifications	 to	the	protocol	 should	 not	be	made	 without	 agreement	 of	the	Investigators	 and	
sponsor .	Changes	 to	the	protocol	 will	require	 written	 IRB/IEC/HREC	 approval/favorable	 opinion	
prior	 to	implementation,	 except	 when	 the	modification	 is	needed	 to	eliminate	 an	immediate	
hazard(s)	 to	patients.	 	The	IRB/IEC/HREC may	provide	 expedited	 review	 and	approval/favorable	
opinion	 for	minor	 change(s)	 in	ongoing	 trials	 that	have	the	approval/favorable	 opinion	 of	the	
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	61IRB/IEC/HREC.		The	Investigator	will	submit	all	protocol	modifications	to	the	IRB/ IEC/HREC	in	
accordance	with the	governing	regulations.
When	immediate	deviation	from	the	protocol	is	required	to	eliminate	an	immediate	hazard(s)	to	
patients,	 the	Investigator	 will	contact	 Sponsor,	 if	circumstances	 permit,	 to	discuss	 the	planned	
course	 of	action.	 	Any	departures	 from	the	protocol	 must	be	fully	documented	 in	the	eCRF	and	
source	documentation.
14.2Source	Documentation
The	Investigator	must	 maintain	detailed	records	of	all	study	participants	who	are	enrolled	in	the	
study	 or	who	undergo	 screening.	 Source	 documents	 include	 patient	 medical	 records	 and	
Investigator’s	 patient	 study	 files,	as	well	as	all	test	results.	 	Information	 required	 for	study	
purposes	 and	any	data	recorded	 in	the	eCRF	 must	 be	supported	 by	appropriate	 source	
documentation.
14.3Direct	Access	to	Source	Documentati on
The	Investigator	 will	ensure	 that	the	Sponsor,	 IRB/IEC/HREC	 and	regulatory	 authorities	 will	
have	direct	 access	 to	all	trial-related	 sites,	source	 data/documents,	 and	reports	 for	the	purpose	
of	monitoring	and	auditing	(ICH[E6]	5.1.2	&	6.10).		This	includ es	electronic	source	data.		
14.4Case	Report	Forms
Case	report	 forms	 (or	an	electronic	 data	capture	 system)	 will	be	provided	 to	each	investigational	
site	for	 the	collection	 of	all	study	 data	for	enrolled	 patients,	 with	the	exception	 of	data	that	may	
be	capture d	externally	to	the	site	(i.e., central	laboratory	data).		Study	site	personnel	will	record	
the	data	in	the	source	 documentation	 and	enter	it	in	the	eCRF	within,	on	average,	 5	business	 days	
of	the	study	 visit,	 while	 carefully	 reviewing	 all	information	 recorded	 for	accuracy	 and	
consistency.	 	Any	required	 data	printouts	 should	 be	filed	in	the	patient’s	 source	 data,	
(i.e.,laboratory	 reports,	 etc.)and	signed/dated	 by	appropriately	 designated	 site	personnel	 as	a	
true	copy	of	the	original.
A	clinical	study	moni tor	will	review	the	eCRFs	and	compare	the	content	to	the	source	data.
The	eCRFs	 for	each	patient	 must	be	reviewed	 and	signed	 by	the	Investigator.	 	This	should	 be	done	
as	soon	as	possible	 after	the	patient	 has	completed	 the	study	 and	all	data	queries	 have	been	
resolved.		
14.5Study	Drug	Accountability
Accountability	 for	study	 drug	at	the	trial	site	is	the	responsibility	 of	the	Investigator.	 	The	
Investigator	 will	ensure	 that	study	 drug	is	used	only	in	accordance	 with	this	protocol.	 	Where	
allowed,	 the	Investigat or	may	choose	 to	assign	 some	 of	the	drug	accountability	 responsibilities	
to	a	pharmacist	 or	other	 appropriate	 individual.	 	Drug	accountability	 records	 indicating	 the	
drugs’	 delivery	 date	to	the	site,	inventory	 at	the	site,	use	by	each	patient,	 and	return	 to	sponsor
(or	disposal	 of	the	drug,	if	approved	 by	sponsor )	will	be	maintained	 by	the	clinical	 site.		These	
records	 will	adequately	 document	 that	the	patients	 were	 provided	 the	drugs	 and	doses	 as	
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	62specified	 in	the	protocol	 and	should	 reconcile	 all	study	 drugs	received	 from	 sponsor .		
Accountability	 records	 will	include	 dates,	 quantities,	 batch/serial	 numbers,	 expiry	 dates	 (if	
applicable),	and	patient	numbers.		 Sponsor or	its	designee	will	review	drug	accountability	at	the	
site	on	an	ongoing	basis	during	monit oring	visits.
14.6Disposal	of	Study	Drug
All	unused	study	drug	will	be	retained	at	the	site	until	inventoried	by	 sponsor /	designee ,	unless	
otherwise	 agreed .		All	unused	 or	expired	study	 drug	will	be	returned	 to	sponsor or	its	designee	
or,	if	authorised	 by	sponsor,	will	be	disposed	 of	at	the	study	 site	and	the	disposal	 will	be	
appropriately	 documented.	 	Records	 shall	be	maintained	 by	the	Investigator	 of	any	such	alternate	
disposition	 of	the	test	drug.		These	records	 must	show	the	identification	 and	quantity	 of	each	unit	
disposed	 of,	the	method	 of	destruction	 (taking	 into	account	 the	requirements	 of	local	law),	and	
the	person/company	who	disposed	of	the	test	substance.		Such	records	must	be	submitted	to	the	
Sponsor	and	copies	on	file	in	the	Investigator’s	Site	Fi le.		All	material	containing	study	drug	will	
be	treated	and	disposed	of	as	hazardous	waste	in	accordance	with	governing	regulations.
14.7Training	of	Staff
The	PI	is	responsible	 for	the	conduct	 of	the	study	 at	this	study	 site,	including	 delegation	 of	
specified	 study	 responsibilities,	 and	training	of	study	 staff.		The	PI	shall	 ensure	 that	the	study	 is	
carried	out	in	accordance	with	the	protocol,	ICH/GCP	guidelines,	and	regulations.
The	PI	will	maintain	a	record	of	all	individuals	involved	in	the	study	(medical,	n ursing	and	other	
staff).		He	or	she	will	ensure	that	appropriate	training	relevant	to	the	study	is	given	to	all	of	these	
staff,	and	that	any	new	information	of	relevance	to	the	performance	of	this	study	is	forwarded	to	
the	staff	involved.
14.8Clinical	Study	Re port
The	Coordinating	 or	Lead	Investigator	 will	be	designated	 toreview	 study	 data	outputs	and sign	
for	the	accuracy	 ofany	associated interim	 clinical	 study	 reports	 and	the	final	clinical	 study	 report	
at	the	end	of	this	study.	 	The	signatory	 Lead	Investigator	 will	be	identified	 by	the	Sponsor	 in	
advance	of	study	completion.
14.9Retention	of	Records
Records	 and	documents	 pertaining	 to	the	conduct	 of	this	study,	 including	 eCRFs,	 source	
documents,	 consent	 forms,	 laboratory	 test	results,	 medication	 inventory	 records and	Investigator	
Site	File,	must	be	retained	 by	the	Investigator	 in	accordance	 with	locally	 applicable	 regulatory	
requirements,	 andin	any	event	 for	a	period	 of	at	least	2	years	 after	the	last	approval	 of	a	
marketing	 application	 in	an	ICH	region	 and	until	there	are	no	pending	 or	contemplated	 marketing	
applications	in	an	ICH	region	or	at	least	2	years	have	elapsed	since	the	formal	disc ontinuation	of	
clinical	 development	 of	the	investigational	product.	 	No	study	 records	 shall	be	destroyed	 without	
notifying	Sponsor	and	giving	Sponsor	the	opportunity	to	take	such	study	records or	authorizing	
in	writing	the	destruction	of	records	after	the	 required	retention	period.
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	6315REFERENCES
Adamo,	A.,	Sese,	B.,	Boue,	S.,	Castano,	J.,	Paramonov,	I.,	Barrero,	M.J.,	Izpisua	Belmonte,	J.C.,	2011.	
LSD1	 regulates	 the	balance	 between	 self-renewal	 and	differentiation	 in	human	
embryonic	stem	cells.	Nat	Cell	Biol	 13,	652-659.
Arber,	 A.A.,	Orazi,	 A.,	Hasserjian,	 R.,	Thiele,	 J.,	Borowitz,	 M.J.,	Le	Beau,	 M.M.,	 Bloomfield,	 C.D.,	
Cazzola,	 M.,	Vardiman,	 J.W.		2016.	 The	2016	 revision	 to	the	World	 Health	 Organization	
classification	of	myeloid	neoplasms	and	acute	leukemia	 Blood	127(20),	2391 -2405
Bannister,	 A.J.,	Kouzarides,	 T.,	2011.	 Regulation	 of	chromatin	 by	histone	 modifications.	 Cell	Res	
21,	381-395.
Barosi,	 G.,	Mesa,	 R.,	Finazzi,	 G.,	Harrison,	 C.,	Kiladjian	 J-J.,	Lengfelder,	 E.,	McMullin	 M.F,	Passamonti,	
F.,	Vannucchi,	A.M.,	Besses,	C.,	Gisslinger,	H.,	Samu elsson,	J.,	Verstovsek,	S.,	Hoffman,	R.H.,	
Pardanani,	 A.,	Cervantes,	 F.,	Tefferi,	 A.	and	Barbui,	 T.	2013	Revised	 response	 criteria	 for	
polycythemia	 vera	and	essential	 thrombocythemia:	 an	ELN	and	IWG-MRT	consensus	
project .	Blood	121,	4778 -4781
Beisel,	C.,	P aro,	R.,	2011.	Silencing	chromatin:	comparing	modes	and	mechanisms.	Nat	Rev	Genet	
12,	123-135.
Bird,	A.	,	2002.	DNA	methylation	patterns	and	epigentic	memory.	Genes	Dev.	16,	6 -21
Chen,	 E.	and	Mullally,	 A.	2014.	 How	 does	 JAKV617F	 contribute	 to	the	pathogene sis	of	
myeloproliferative	 neoplasms?	 Hematology	 (American	 Society	 of	Hematology	 Education)	
268-276
Foster,	 C.T.,	Dovey,	O.M.,	Lezina,	L.,	Luo,	J.L.,	Gant,	T.W.,	Barlev,	N.,	Bradley,	A.,	Cowley,	S.M.,	2010.	
Lysine -specific	 demethylase	 1	regulates	 the	embryonic	 transcriptome	 and	CoREST	
stability.	Mol	Cell	Biol	 30,	4851 -4863.
Goardon,	N.,	Marchi,	E.,	Atzberger,	A.,	Quek,	L.,	Schuh,	A.,	Soneji,	S.,	Woll,	P.,	Mead,	A.,	Alford,	K.A.,	
Rout,	R.,	Chaudhury,	S.,	Gilkes,	A.,	Knapper,	S.,	Beldjord,	K.,	Begum,	S.,	Rose,	S.,	Geddes,	N.,	
Griffiths,	 M.,	Standen,	 G.,	Sternberg,	 A.,	Cavenagh, J.,	Hunter,	 H.,	Bowen,	 D.,	Killick,	 S.,	
Robinson,	 L.,	Price,	 A.,	Macintyre,	 E.,	Virgo,	 P.,	Burnett,	 A.,	Craddock,	 C.,	Enver,	 T.,	Jacobsen,	
S.E.,	Porcher,	 C.,	Vyas,	P.	2011.	 Coexistence	 of	LMPP-like	and	GMP-like	leukemia	 stem	cells	
in	acute	myeloid	leukemi a.	Cancer	Cell	 19,	138-152.
Harris,	 W.J.,	Huang,	 X.,	Lynch,	 J.T.,	Spencer,	 G.J.,	Hitchin,	 J.R.,	Li,	Y.,	Ciceri,	 F.,	Blaser,	 J.G.,	Greystoke,	
B.F.,	Jordan,	 A.M.,	Miller,	 C.J.,	Ogilvie,	 D.J.,	Somervaille,	 T.C.,	2012.	 The	histone	 demethylase	
KDM1A	 sustains	th e	oncogenic	potential	 of	MLL -AF9	leukemia	stem	cells.	Cancer	Cell	 21,	
473-487.
Jones	 A	(VP	Cliical	 Operation,	 Imago	 BioSciences).	 Global	 Study	 Reference	 Manual;	 Version	 2.0.	
Redwood	 City	(CA):	Imago	 BioSciences,	 Inc.;	2021	Dec	2.	24	p.	Protocol	 No.:	IMG-7289-
CTP-202.
Kahl,	P.,	Gullotti,	L.,	Heukamp,	L.C.,	 Wolf,	S.,	Friedrichs,	 N.,	Vorreuther,	 R.,	Solleder,	 G.,	Bastian,	 P.J.,	
Ellinger,	 J.,	Metzger,	 E.,	Schule,	 R.,	Buettner,	 R.,	2006.	 Androgen	 receptor	 coactivators	
lysine -specific	 histone	 demethylase	 1	and	four	and	a	half	LIM	domain	 protein	 2	predict	
risk	of	prostate	cancer	recurrence.	Cancer	Res	 66,	11341 -11347.
Kerenyi,	 M.A.,	Shao,	Z.,	Hsu,	Y.J.,	Guo,	G.,	Luc,	S.,	O'Brien,	 K.,	Fujiwara,	 Y.,	Peng,	C.,	Nguyen,	 M.,	Orkin,	
S.H.,	2013.	 Histone	 demethylase	 Lsd1	represses	 hematopoietic	 stem	and	progenitor	 cell	
signatures	during	blood	cell	maturation.	 Elife	2,	e00633.
Klose,	 R.J.,	Kallin,	 E.M.,	 Zhang,	 Y.,	2006.	 JmjC-domain -containing	 proteins	 and	histone	
demethylation.	Nat	Rev	Genet	 7,	715-727.
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	64Kornberg,	 R.	D.,	1974.	 Chromatin	 structure:	 a	repeating	 unit	of	histones	 and	DNA.	Science	 184,	
868–871
Kouzarides,	T.,	2007.	Ch romatin	modifications	and	their	function.	Cell	128:	693	 -705
Lara-Astiaso,	D.,	 Weiner,	A.,	 Lorenzo -Vivas,	 E.,	Zaretsky,	 I.,	Jaitin,	D.A.,	 David,	E.,	 Keren -Shaul,	 H.,	
Mildner,	A.,	Winter,	D.,	Jung,	S.,	Friedman,	N.,	Amit,	I.,	2014.	Immunogenetics.	Chromatin
state	dynamics	during	blood	formation.	Science	 345,	943-949.
Lee,	M.G.,	Wynder,	 C.,	Cooch,	 N.,	Shiekhattar,	 R.,	2005.	 An	essential	 role	for	CoREST	 in	nucleosomal	
histone	3	lysine	4	demethylation.	Nature	 437,	432-435.
Lim,	S.,	Janzer,	 A.,	Becker,	 A.,	Zimme r,	A.,	Schule,	 R.,	Buettner,	 R.,	Kirfel,	 J.,	2010.	 Lysine -specific	
demethylase	 1	(LSD1)	 is	highly	 expressed	 in	ER-negative	 breast	 cancers	 and	a	biomarker	
predicting	aggressive	biology.	Carcinogenesis	 31,	512-520.
Lin,	X.M.,	Zhong,	 W.T.,	Wang,	 C.L.,	Wang,	 S.Q.,	2011.	 [Expression	 of	histone	 demethylase	 lysine	
specific	demethylase	1	in	acute	leukemia	and	its	clinical	significance].	Zhongguo	Shi	Yan	
Xue	Ye	Xue	Za	Zhi	 19,	1348 -1352.
Lin,	Y.,	Wu,	Y.,	Li,	J.,	Dong,	 C.,	Ye,	X.,	Chi,	Y.I.,	Evers,	 B.M.,	Zhou,	 B.P.,	2010.	The	SNAG	 domain	 of	
Snail1	 functions	 as	a	molecular	 hook	for	recruiting	 lysine -specific	 demethylase	 1.	EMBO	
J	29,	1803 -1816.
Metzger,	 E.,	Wissmann,	 M.,	Yin,	N.,	Muller,	 J.M.,	Schneider,	 R.,	Peters,	 A.H.,	Gunther,	 T.,	Buettner,	
R.,	Schule,	 R.,	2005.	 LSD1	demethylates	 repressive	histone	 marks	 to	promote	 androgen -
receptor -dependent	transcription.	Nature	 437,	436-439.
Niebel,	 D.,	Kirfel,	 J.,	Janzen,	 V.,	Holler,	 T.,	Majores,	 M.,	Gutgemann,	 I.	2014.	 Lysine -sepcific	
demethylase	1	(LSD1)	in	haematopoietic	and	l ympoid	neoplasms	Blood	124(1):151 -152
Orkin,	 S.H.,	Hochedlinger,	 K.,	2011.	 Chromatin	 connections	 to	pluripotency	 and	cellular	
reprogramming.	Cell	 145,	835-850.
Rhodes,	 D.R.,	Kalyana -Sundaram,	 S.,	Mahavisno,	 V.,	Varambally,	 R.,	Yu,	J.,	Briggs,	 B.B.,	Barrette,	
T.R.,	Anstet,	 M.J.,	Kincead -Beal,	C.,	Kulkarni,	 P.,	Varambally,	 S.,	Ghosh,	D.,	 Chinnaiyan,	 A.M.,	
2007.	 Oncomine	 3.0:	genes,	 pathways,	 and	networks	 in	a	collection	of	18,000	 cancer	 gene	
expression	profiles.	Neoplasia	 9,	166-180.
Saleque,	 S.,	Kim,	J.,	Rooke,	 H.M.,	 Orkin,	 S.H.,	2007.	 Epigenetic	 regulation	 of	hematopoietic	
differentiation	 by	Gfi-1	and	Gfi-1b	is	mediated	 by	the	cofactors	 CoREST	 and	LSD1.	 Mol	
Cell	27,	562-572.
Schulte,	 J.H.,	Lim,	S.,	Schramm,	 A.,	Friedrichs,	 N.,	Koster,	 J.,	Versteeg,	 R.,	Ora,	I.,	Pajtler,	 K.,	Klein-
Hitpass,	 L.,	Kuhfittig -Kulle,	 S.,	Metzger,	 E.,	Schule,	 R.,	Eggert,	 A.,	Buettner,	 R.,	Kirfel,	 J.,	2009.	
Lysine -specific	 demethylase	 1	is	strongly	 expressed	 in	poorly	 differentiated	
neuroblastoma:	implications	for	therapy.	Cancer	Res	 69,	2065 -2071.
Shi,	Y.,	Lan,	F.,	Matson,	 C.,	Mulligan,	 P.,	Whetstine,	 J.R.,	Cole,	P.A.,	Casero,	 R.A.,	Shi,	Y.,	2004.	 Histone	
demethylation	 mediated	 by	the	nuclea r	amine	 oxidase	 homolog	 LSD1.	 Cell	119,	941-953.
Shi,	Y.J.,	Matson,	 C.,	Lan,	F.,	Iwase,	 S.,	Baba,	 T.,	Shi,	Y.,	2005.	 Regulation	 of	LSD1	 histone	
demethylase	activity	by	its	associated	factors.	Mol	Cell	 19,	857-864.
Somervaille,	T.C.,	Cleary,	M.L.,	2006.	Ide ntification	and	characterization	of	leukemia	stem	cells	in	
murine	MLL -AF9	acute	myeloid	leukemia.	Cancer	Cell	 10,	257-268.
Somervaille,	 T.C.,	Matheny,	 C.J.,	Spencer,	 G.J.,	Iwasaki,	 M.,	Rinn,	 J.L.,	Witten,	 D.M.,	Chang,	 H.Y.,	
Shurtleff,	 S.A.,	Downing,	 J.R.,	Cleary,	 M.L.,	2009.	 Hierarchical	 maintenance	 of	MLL	myeloid	
leukemia	 stem	cells	employs	 a	transcriptional	 program	 shared	 with	embryonic	 rather	
than	adult	stem	cells.	Cell	Stem	Cell	 4,	129-140.
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	65Sprussel,	A.,	Schulte,	J.H.,	Weber,	S.,	Necke,	M.,	Handschke,	K.,	Thor,	T.,	Pajtler,	K.W.,	Schramm,	A.,	
Konig,	 K.,	Diehl,	 L.,	Mestdagh,	 P.,	Vandesompele,	 J.,	Speleman,	 F.,	Jastrow,	 H.,	Heukamp,	
L.C.,	Schule,	 R.,	Duhrsen,	 U.,	Buettner,	 R.,	Eggert,	 A.,	Gothe rt,	J.R.,	2012.	 Lysine -specific	
demethylase	 1	restricts	 hematopoietic	 progenitor	 proliferation	 and	is	essential	 for	
terminal	differentiation.	Leukemia	 26,	2039 -2051.
Thiele,	 J.,	Kvasnicka,	 H.M.,	Facchetti,	 F.,	Franco,	 V.,	van	der	Walt,	 J.,	Orazi,	 A.	2005.	 European	
consensus	 on	grading	bone	marrow	fibrosis	and	assessment	of	cellularity	Haematologica	
90(8),	1128 -1132
Wang,	J.,	Hevi,	S.,	Kurash,	J.K.,	Lei,	H.,	Gay,	F.,	Bajko,	J.,	Su,	H.,	Sun,	W.,	Chang,	H.,	Xu,	G.,	Gaudet,	F.,	
Li,E.,	Chen,	 T.,	2009.	 The	lysine	 demethylase	 LSD1	(KDM1)	 is	required	 for	maintenance	
of	global	DNA	methylation.	Nat	Genet	 41,	125-129.
Wang,	 J.,	Scully,	 K.,	Zhu,	X.,	Cai,	L.,	Zhang,	J.,	Prefontaine,	G.G.,	Krones,	A.,	Ohgi,	 K.A.,	Zhu,	P.,	Garcia -
Bassets,	 I.,Liu,	F.,	Taylor,	 H.,	Lozach,	 J.,	Jayes,	 F.L.,	Korach,	 K.S.,	Glass,	 C.K.,	Fu,	X.D.,	
Rosenfeld,	 M.G.,	 2007.	 Opposing	 LSD1	 complexes	 function	 in	developmental	 gene	
activation	and	repression	programmes.	Nature	 446,	882-887.
Whyte,	 W.A.,	Bilodeau,	 S.,	Orlando, D.A.,	Hoke,	 H.A.,	Frampton,	 G.M.,	Foster,	 C.T.,	Cowley,	 S.M.,	
Young,	 R.A.,	2012.	 Enhancer	 decommissioning	 by	LSD1	 during	 embryonic	 stem	 cell	
differentiation.	Nature	 482,	221-225.
Whyte,	 W.A.,	 Orlando,	 D.A.,	Hnisz,	 D.,	Abraham,	 B.J.,	Lin,	C.Y.,	Kagey,	 M.H.,	Rahl,	 P.B.,	Lee,	T.I.,	
Young,	 R.A.,	2013.	 Master	 transcription	 factors	 and	mediator	 establish	 super-enhancers	
at	key	cell	identity	genes.	Cell	 153,	307-319.
Wouters,	 B.J.,	Lowenberg,	 B.,	Erpelinck -Verschueren,	 C.A.,	van	Putten,	 W.L.,	Valk,	P.J.,	Delwel,	 R.,	
2009.	 Double	 CEBPA	 mutations,	 but	not	single	 CEBPA	 mutations,	 define	 a	subgroup	 of	
acute	 myeloid	 leukemia	 with	a	distinctive	 gene	 expression	 profile	 that	is	uniquely	
associated	with	a	favorable	outcome.	Blood	 113,	3088 -3091.
Yang.	 J.,	Huang,	 J.,	Dasgup ta,	M.,	Sears,	 N.,	Miyagi,	 M.,	Wang,	 B.,	Chance,	 M.R.,	Chen,	 X.,	Du,	Y.,	Wang,	
Y.,	An,	L.,	Wang,	 Q.,	Lu,	T.,	Zhang,	X.,	Wang,	 Z.,	Stark,	G.R.	 2010	Reversible	 methylation	of	
promoter -bound	 STAT3	 by	histone -modifying	 enzymes	 Proc	Nat	Acad	 Sci	107(50),	
21499 -21504Zhang,	W.,	Zecca,	L.,	Wilson,	B.,	Ren,	H.W.,	Wang,	Y.J.,	Wang,	X.M.,	Hong,	J.S.,	
2013.	 Human	 neuromelanin:	 an	endogenous	 microglial	 activator	 for	dopaminergic	
neuron	death.	Front	Biosci	(Elite	Ed)	 5,	1-11.
Zhang,	 W.,	Zecca,	 L.,	Wilson,	 B.,	Ren,	H.W.,	 Wang,	 Y.J.,	Wang,	 X.M.,	Hong,	 J.S.,	2013.	 Human	
neuromelanin:	 an	endogenous	 microglial	 activator	 for	dopaminergic	 neuron	 death.	 Front	
Biosci	(Elite	Ed)	5,	1 -11
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	6616APPENDICES
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	67
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	68
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	69
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	70
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	71
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	72
CCI
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	7316.2Criteria	for	Grading	 Myelofibrosis	(Arber	 et	al.,	2016)*	
Fibrosis	grade Definition
MF-0 Scattered	linear	reticulin	with	no	 intersections	(crossovers)	corresponding	to	normal	bone	marrow
MF-1 Loose	network	of	reticulin	with	many	intersections,	especially	in	perivascular	areas
MF-2 Diffuse	and	dense	increase	in	reticulin	with	extensive	intersections,	occasionally	with	 focal	bundles	of	thick	fibers	mostly	
consistent	with	collagen,	and/or	focal	osteosclerosis a
MF-3 Diffuse	and	dense	increase	in	reticulin	with	extensive	intersections	and	coarse	bundles	of	thick	fibers	consistent	with	colla gen,	
usually	associated	with	ost eosclerosis a
*Slightly	modified	from	the	European	Consensus	Criteria	as	presented	in	 Thiele	 et	al.,	2005
Semiquantitative	grading	of	BM	fibrosis	with	minor	modifications	concerning	collagen	and	osteosclerosis. Fiber	density	should	be	assessed	only	in	 hematopoietic	areas.		
aIn	grades	MF -2	or	MF -3	an	additional	trichrome	stain	is	recommended.		
16.3Eastern	Cooperative	Group	Performance	Status
Grade ECOG	Performance	Status
0 Fully	active,	able	to	carry	on	all	 pre-disease	performance	without	restriction
1 Restricted	in	physically	strenuous	activity	but	ambulatory	and	able	to	carry	out	work	of	a	light	or	sedentary	nature,	e.g.,	l ight	house	work,	
office	work
2 Ambulatory	and	capable	of	all	self -care	but	unable	t o	carry	out	any	work	activities;	up	and	about	more	than	50%	of	waking	hours
3 Capable	of	only	limited	self -care;	confined	to	bed	or	chair	more	than	50%	of	waking	hours
4 Completely	disabled;	cannot	carry	on	any	self -care;	totally	confined	to	bed	or	 chair
5 Dead
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	7416.4Revised	IWG -MRT	and	ELN	Response	Criteria	for	MF
Response	
categoriesRequired	criteria	(for	all	response	categories,	benefit	must	last	for	 ≥12	weeks	to	qualify	as	a	response)
CRBone	marrow:*	 Age-adjusted	 normocellularity;	< 5%	blasts;	 ≤grade	1	MF †and
Peripheral	blood:	 Haem oglobin	 ≥100	g/L	and	< UNL;	neutrophil	count	 ≥	1	x109/L	and	< UNL;Platelet	count	 ≥100x109/L	and	
<UNL;	< 2%	immature	myeloid	cells‡	and
Clinical:	Resolution	of	disease	 symptoms;	spleen	and	liver	not	palpable;	no	evidence	of	EMH
PRPeripheral	blood:	 Haemoglobin	 ≥100	g/L	and	< UNL;	neutrophil	count	 ≥1	x109/L	and	< UNL;	 platelet	count	 ≥100	x	109/Land	
<UNL;	< 2%	immature	myeloid	cells ‡and
Clinical:	Resolution	of	 disease	symptoms;	spleen	and	liver	not	palpable;	no	evidence	of	EMH	or
Bone	marrow:*	 Age-adjusted	normocellularity;	< 5%	blasts;	 ≤grade	1	MF†,	and	peripheral	blood:	 Haem oglobin	 ≥85	but	<100	
g/L	and	< UNL;	neutrophil	count	 ≥1	x109/L	and	< UNL;	platelet	coun t	≥50,	but	<100	x 109/L	and	< UNL;	<2%	immature	
myeloid	cells ‡and
Clinical:	Resolution	of	disease	symptoms;	spleen	and	liver	not	palpable;	no	evidence	of	EMH	
Clinical	
improvement	(CI)The	achievement	of	an aemia,	spleen	or	symptoms	response	without	prog ressive	disease	or	 increase	in	severity of	anaemia,	
thrombocytopenia ,	or	neutropenia §
Anaemia	responseTransfusion -independent	patients:	a	 ≥20	g/L	increase	in	 haemoglobin	level ¶
Transfusion -dependent	patients:	becoming	 transfusion -independent {
Spleen	responseA	baseline	splenomegaly	that	is	palpable	at	5 -10	cm,	below	the	LCM ,	becomes	not	palpable** or
A	baseline	sp lenomegaly	that	is	palpable	at	> 10	cm,	be low	the	LCM,	decreases	by	 ≥50%**
A	baseline	sp lenomegaly	that	is	palpable	at	< 5	cm,	below	the	LCM,	is	not	eligible	for	spleen	response
A	spleen	response	requires	confirmation	by	MRI	or	computed	tomography	showing	 ≥35%	spleen	volume	reduction
Symptoms	
responseA	≥50%	reduction	in	the	MPN -SAF	TSS††
Progressive	
disease‡‡Appearance	of	a	new	splenomegaly	that	is	palpable	at	least	5	cm	below	the	LCM	or
A	≥100%	increase	in	palpable	distance,	below	LCM,	for	baseline	splenomegaly	of	5 -10	cm	or
A	50%	increase	in	palpable	distance,	below	LCM ,	for	baseline	splenomegaly	of	> 10	cm	or
Leukaem ic	transformation	confirmed	by	a	bone	marrow	blast	count	of	 ≥20%	or
A	peripheral	blood	blast	content	of	 ≥20%	associated	with	an	absolute	blast	count	of	 ≥1	x	10 9/L	that	lasts	for	at	least	2	weeks
Stable	 disease Belonging	to	none	of	the	above	listed	response	categories
RelapseNo	longer	meeting	criteria	for	at	least	CI	after	achieving	CR,	PR,	or	CI,	or
Loss	of	an aemia	response	persisting	for	at	least	1	month	or
Loss	of	spleen	response	 persisting	for	at	least	1	month
EMH,	extramedullary	 haematopoiesis	(no	evidence	of	EMH	implies	the	absence	of	pathology -or	imaging	study -proven	non -hepatosplenic	EMH);	LCM,	left	costal	margin;	
UNL,	upper	normal	limit.	
*Baseline	and	post -treatment	bone	marrow	slides	are	to	be	interpreted	at	one	sitting	by	a	central	review	process.	
†Grading	 of	MF	is	according	 to	the	European	 classi ication	 Thiele	 et	al.	European	 consensus	 on	grading	 bone	 marrow	 fibrosis	 and	assessment	 of	cellularity.	 It	is	
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	75underscored	 that	the	consensus	 definition	 of	a	CR	bone	 marrow	 is	to	be	used	only	in	those	 patients	 in	which	 all	other	 criteri a	are	met,	including	 resolution	 of	
leukoerythroblastosis.		
‡Immature	 myeloid	 cells	constitute	 blasts	 +	promyelocytes	 +	myelocytes	 +	metamyelocytes	 +	nucleated	 red	blood	 cells.		In	splenectomized	 patients,	 <5%	immature	
myeloid	cells	are	allowed.	
§See	above	 for	definitions	 of	anaemia	response,	 spleen	 response,	 and	progressive	disease.	 Increase	in	 severity	of	an aemia	constitutes	 the	occurrence	 of	new	transfusion	
dependency	 or	a	≥20	g/L	decrease	 in	haemoglobin	 level	from	pretreatment	 baseline	 that	lasts	for	at	least	12	weeks.	 	Increase	 in	severity of	thrombocytopenia	 or	
neutropenia	 is	defined	 as	a	2-grade	 decline,	 from	pretreatment	 baseline,	 in	platelet	 or	absolute	 neutrophil	 count,	 according	 to	the	Common	 Terminology	 Criteria	for	
Adverse	Events	(CTCAE)	version	4.0.		In	addition,	assignment	to	CI	r equires	a	minimum	platelet	count	of	 ≥25000	x	10 9/L	and	absolute	neutrophil	count	of	 ≥0.5	x	10 9/L.	
¶Applicable	only	to	patients	with	baseline	 haemoglobin	of	<100	g/L.	
{Transfusion	dependency	before	study	enrollment	is	defined	as	transfusions	of	at	 least	6	units	of	packed	red	blood	cells	(PRBC),	in	the	12	weeks	prior	to	study
enrollment,	 for	a	haemoglobin	 level	of	<	85	g/L,	in	the	absence	 of	bleeding	 or	treatment -induced	 anaemia.	 In	addition,	 the	most	recent	 transfusion	 episode	 must	have	
occurred	in the	28	days	prior	to	study	enrollment.	Response	in	transfusion -dependent	patients	 requires	 absence	of	 any	PRBC	transfusions	during	any	consecutive	“rolling”	
12-week interval	during	the	treatment	phase,	capped	by	a	h aemoglobin	level	of	 ≥	85	g/L.
**Spleen	re sponse	must	be	confirmed	by	imaging	studies	where	a	 ≥35%	reduction	in	spleen	volume,	as	assessed	by	MRI	or	CT,	is	required.	F urthermore,	a	 ≥35%	volume	
reduction	in	the	spleen,	by	MRI	or	CT,	constitutes	a	response	regardless	of	what	is	reported	with	physica l	examination.	
††Symptoms	 are	evaluated	 by	the	MPN-SAF	TSS.		The	MPN-SAF	TSS	is	assessed	 by	the	patients	 themselves	 and	includes	 fatigue,	 concentration,	 early	satiety,	 inactivity,	
night	sweats,	 itching,	 bone	pain,	abdominal	 discomfort,	 weight	 loss,	and	fevers.		Scoring	 is	from	0	(absent/as	 good	as	it	can	be)	to	10	(worst	 imaginable/as	bad	 as	it	can	
be)	for	each	item.		The	MPN -SAF	TSS	is	the	summation	of	all	the	individual	scores	(0 -100	scale).	Symptoms	response	requires	 ≥50%	reduction	in	the	MPN -SAF	TSS.	
‡‡Progressive	 disease	 assignment	 for	splenomegaly	 requires	 con irmation	 by	MRI	or	computed	 tomography	 showing	 a	≥25%	 increase	 in	spleen	 volume	 from	baseline.	
Baseline	values	for	both	physical	examination	and	imaging	studies	refer	to	pretreatment	baseline	a nd	not	to	post -treatment	measurements.
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	7616.5Revised	Response	Criteria	for	ET:		IWG -MRT	and	ELN	Consensus	2013	 (Barosi	et	al.,	
2013)
Response	
CategoriesCriteria
Complete	
Remission
A Durable*	resolution	of	disease -related	signs	 including	palpable	
hepatosplenomegaly,	large	symptoms	improvement, †AND	
B Durable*	peripheral	blood	count	remission,	defined	as:	
platelet	count	 ≤400	x	10 9/L,	WBC	count	<10	x	10 9/L,	absence	of	
leukoerythroblastosis,	AND	
CWithout	signs	of	progressive	disease,	and	absence	of	any	hemorrhagic	or	
thrombotic	events,	AND	
D Bone	marrow	histological	remission	defined	as	disappearance	of	megakaryocyte	
hyperplasia	and	absence	of	>grade	1	reticulin	fibrosis.
Partial	
Remission
A Durable*	resolution	of	disease -related	signs	including	palpable	
hepatosplenomegaly,	and	large	symptoms	improvement,	AND	
B Durable*	peripheral	blood	count	remission,	defined	as:	
platelet	count	 ≤400	x	10 9/L,	WBC	count	<10	x	10 9/L,	absence	of
leukoerythroblastosis,	AND	
CWithout	signs	of	progressive	disease,	and	absence	of	any	hemorrhagic	or	
thrombotic	events,	AND	
D Without	bone	marrow	histological	remission,	defined	as	the	persistence	of	
megakaryocyte	hyperplasia.
No	Response Any	response	that	does	not	satisfy	partial	remission	
Progressive	
DiseaseTransformation	into	PV,	post -ET	myelofibrosis,	myelodysplastic	syndrome	or	
acute	leukemia ‡
Molecular	response	is	not	required	for	assignment	as	complete	response	or	partial	response.	Molecular	response	
evaluation	requires	analysis	in	peripheral	blood	granulocytes.	Complete	response	is	defined	as	eradication	of	a	
preexisting	abnormality.	Partial	 response	applies	only	to	patients	with	at	least	20%	mutant	allele	burden	at	
baseline.	Partial	response	is	defined	as	 ≥50%	decrease	in	allele	burden.	
WBC,	white	blood	cell.	
*Lasting	at	least	12	wk.	
†Large	symptom	improvement	( ≥10-point	decrease)	in	MPN -SAF	TSS.	
‡For	the	diagnosis	of	PV	see	World	Health	Organization	criteria	(WHO); for	the	diagnosis	of	post -ET	
myelofibrosis,	see	the	
IWG-MRT	criteria;	for	the	diagnosis	of	myelodysplastic	syndrome	and	acute	leukemia,	see	WHO	criteria.
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	7716.6Myeloprolif erative	Neoplasm	Symptom	Assessment	Form	Total	Symptom	Score	
(MPN-SAF	TSS) –7-Day	Recall
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	7816.7Myeloproliferative	Neoplasm	Symptom	Assessment	Form	(MPN -SAF)	
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	79
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	8016.8Patient	Global	Impression	of	Change
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	8116.9Remote	Data	Review
16.9.1 Risk	Assessment
Sponsor will	remain	responsive	 where	possible,	 to	the	 remote	data	review requirements	of	each	
individual	 siteregarding how	patient	 visits	 and	monitoring	 visits	 can	occur remotely,	 when	
possible.
16.9.2 Security	Measures
Monitors areonlypermitted toundertake remote datareview through theprocesses detailed
below inSections 16.9.3.1 and16.9.3.2 (EMR access orvideo call/conferencing) where the
following security measures areinplace:
Location ofMonitor: remote datareview activities maybeperformed inlocations that
donotallow access/viewing byunauthorized thirdparties:
oAcceptable locations include: closed room inaSyneos Health office, athomein
private areaforhome-based staff.
oExamples ofprohibited locations include: Open plandesk space inSyneos
Health offices, onpublic transportation, inairport lounge orother public areas.
Internet connection: remote datareview ispermi ttedonlythrough asecure internet
connection (i.e.,Syneos Health office internet orsecure personal internet afterlogging
intoSyneos Health virtual private network [VPN]).Useofapublic internet, hotspotor
hotelinternet isprohibited.
Device: remote datareview ispermitted onlythroug hSyneos Health registered device
(e.g.,laptop,iPad)orthrough adevice provided bythesite.
While theEMRsystem isaccessed orvideo call/conference areongoing, thecomputer
mustbelocked ifleftunattended.
16.9.3 Processes
As	outlined	 in	Section 13.5,	remote	 data	review	 is	intended	 to	encompass	 as	many	 activities	
performed	 in	a	routine	 on-site	monitoring	 visit	as	is	functionally	 possible,	 and	as	permitted	 by	
site	policy	 and	procedure .		Thesource	 documents/source	 data	to	be	made	 available	 for	remote	
data	review	 include	 those	 related	 to	the	primary	 endpoint	 and	exploratory	 endpoints,	 safety,	
study	drug	dispensation	and	return	and	the	reasons	for	exclusion	of	a	subject	from	the	trial.
The	remote	review	 of	data	may	be	actioned	 viamultiple	 pathways,	 often	 contingent	 on	site’s	
capabilities.		 Examples	include:
Remote	Source	Data	 Review (via	Electronic	Medical	Records	(EMR) )
Remote	Source	Data	 Review (via	video	call/conferencing)
Remote	Data	Verif ication	( using	 redacted	source	documents)
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	82Additionally,	 to	facilitate	 continued	 interaction	 with	and	support	 of	the	site,	phone	 monitoring	
visits	 may	also	periodically	 be	conducted.	 Remote	 review	 of	data	will	not	occur	 during	 phone	
visits.
16.9.3.1 Direct, Controll edRemote Access totheSystems UsedbytheTrialSiteto
Manage theSource Documents/ Source Data
For	data	review	 whereby	 the	monitor	 accesses	 the	EMR	 system	 remotely,	 the	following	 criteria	
are	required	to	be	met	before	this	process	can	be	 implemented	for	any	subject:
Anaudittrailisavailable intheElectronic Medical Records (EMR) system.
There isunique password access totheEMRsystem assigned toeachmember ofsitestaff.
There isunique password, read-onlyaccess totheEMRsystem assigned totheMonitor.
EMRaccess hasbeengranted onlytotrialsubjects’ records andother patient dataisnot
accessible totheMonitor (unless aprocedure isinplacetomonitor theMonitor’s activity
following eachsession) .			
USsitesonly:written procedure isinplacefortheuseofEMRsystem.
USsitesonly:IftheEMRsystem iscertified bytheOffice oftheNational Coordinator for
Health Information Technology (ONC) attheDepartment ofHealth andHuman Services,
itissufficient toconfirm thisontheCOVID -19Remote Source DataMonitoring Site
Agreement.
16.9.3.2 ForPassive Access toOriginal Documents/ Original DataviaLiveImage
Transmission
The	following	controls	will	be	applied	for	remote	data	review	by	video	call/conferencing:
Thevideocall/conference mayonlyoccur using aSyneos Health approved information
andcommunication technology.
Video review ofdocumentation onlyispermitted.
Norecording oftheinteraction ispermitted.
Nodocument upload ispermitted.
Nodocument storage ispermitted.
Usage mustcomply withapplicable localregulations/ regulatory guidance.
During remote datareview byvideo call/conferencing carewillbetaken toavoid
inadvertent viewing ofindividuals whoshould notbepartoftheinteraction.
16.9.3.3 Passing	 on	Redacted	 Copies	 of	Original	 Documents	 and	Documents	 with	
Original	Data
Note:		In	Germany,	the	sending	of	redacted	source	data	is	generally	not	permissible	as	a	method	
for	the	remote	 review	 of	data;	however,	 single	 redacted	 documents	 may	be	used	at	times	 to	
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	83confirm	an	individual	data -point.	
The	following	 controls	 will	be	applied	 during	 for	passing	 on	redacted	 copies	 of	original	
documents :
Process	 must	 beallowed	 by	local	 regulations and	in	compliance	 with	applicable	
regulatory	guidance
PI	to	document	 the	delegation	 of	creation	 of	Pseudonymized	 Certified	 Copies	 of	the	
source	documents	on	the	Study	Personnel	Signature	and	Delegation	Form
Site	staff	who	will	provide	 source	 documents	 to	Monitor	 for	remote	 data	review	 will	be
trainedon	the	role,	responsibility,	 and	process	 for	providing	 pseudonymized	 Certified	
Copies	of	source	documents	to	support	 remote	review	of	data
Certified	Copies	of	all	required	original	source	documents will	be	prepared
Certified	 Copy:	A	copy	(irrespective	 of	the	type	of	media	used)	of	the	original	record	that	
has	been	verified	(i.e.,	by	a	dated	signature	 or	by	generation	 through	a	validated	process)	 to	
have	the	same	information,	 including	 data	that	describe	the	context,	content,	andstructure,	
as	the	original.	 (International	 Council	for	Harmonisation	(ICH)	Guideline	 for	Good	 Clinical	
Practice	(GCP)	Revision	2).
Note:	A	copy	is	certified	by	signing	and	dating	on	the	first	page	with	a	statement	“certified	
copy”	and	adding	a	note	on	the	first	page	that	the	certified	copy	package	consists	of	#	pages.
Each	page	must	be	numbered	 so	that,	in	total,	the	pages	match	the	full	#	of	pages	
documented	on	the	first	page	of	the	package.
All	subject direct	 identifiers	 (e.g.,name,	 social	 security/national identification	 number,	
medical	 record	 number,	 initials,	 full	date	of	birth,	 home	 address ,etc.)	will	beredacted/
obscured (i.e.,pseudonymized)	 on	the	copies to	protect subject	 confidentiality	 and	
personal	data.
A	quality	 check	 of	the	redacted	 Certified	 Copies	 will	be	performed	 by	asecond	 site	staff	
member	 to	confirm	 all	subject	 directly	 identifiable	 information	 has	been	redacted ,the	
correct	subject	identification	code	added and	that	the	copies	are	legible .	
oThe	quality	 check	 will	be	documented	 by	the	second	 site	staff	member’s	 initials,
dating ofthe	first	page	 of	the	package	 and	addition	 of	thestatement	
“QC’d/Checked”
Atransmittal	 form	will	be	completed	 each	timePseudonymized	 Certified	 Copies	 of	source	
documents are	sent .	
The	prepared	 source	d ocument	package,	including	transmittal	form ,	will	be	provided by	
one	of	the	following	methods:
oOvernight	Courier
oSecure	Fax	Transmission	
08WYVV
Imago	BioSciences,	Inc. ,	a	subsidiary	of	 Merck	&	Co.,	Inc. Protocol	 IMG-7289-CTP-202/	MK-3543-005
Bomedemstat	( IMG-7289/MK-3543) 13	December	2023
Page	84oScanned	 images	 via	secure	 email	 (encrypted	 email	 or	password	 protected	 email	
attachment.	 If	the	latter,	 the	password	 will	be	provided	 to	Monitor	 via	telephone)
oAsecure platform	for	document	exchange
Aset	of	the	prepared	 source	 document	 package,	 including	 transmittal	 form,	will	be	
retained in	the	Investigator’s	 Site	File.Note:	 These	 documents	 will	not	be	retained	 in	
Germany.
08WYVV